VEEVA SYSTEMS INC, 10-K filed on 3/30/2022
Annual Report
v3.22.1
Cover Page - USD ($)
$ in Billions
12 Months Ended
Jan. 31, 2022
Feb. 28, 2022
Jul. 31, 2021
Document And Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Jan. 31, 2022    
Current Fiscal Year End Date --01-31    
Document Transition Report false    
Entity File Number 001-36121    
Entity Registrant Name Veeva Systems Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-8235463    
Entity Address, Address Line One 4280 Hacienda Drive    
Entity Address, City or Town Pleasanton    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94588    
City Area Code 925    
Local Phone Number 452-6500    
Title of 12(b) Security Class A Common Stock,par value $0.00001 per share    
Trading Symbol VEEV    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 46.2
Documents Incorporated by Reference Portions of the Registrant’s Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Form 10-K to the extent stated herein. The proxy statement will be filed by the Registrant with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended January 31, 2022.    
Amendment Flag false    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001393052    
Class A common stock      
Document And Entity Information [Line Items]      
Entity Common Stock, Shares Outstanding (in shares)   139,594,253  
Class B common stock      
Document And Entity Information [Line Items]      
Entity Common Stock, Shares Outstanding (in shares)   14,764,740  
v3.22.1
Audit Information
12 Months Ended
Jan. 31, 2022
Audit Information [Abstract]  
Auditor Firm ID 185
Auditor Name KPMG LLP
Auditor Location Santa Clara, California
v3.22.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Current assets:    
Cash and cash equivalents $ 1,138,040 $ 730,504
Short-term investments 1,238,064 933,122
Accounts receivable, net of allowance for doubtful accounts of $473 and $193, respectively 631,134 564,387
Unbilled accounts receivable 63,266 47,206
Prepaid expenses and other current assets 36,679 35,607
Total current assets 3,107,183 2,310,826
Property and equipment, net 54,495 53,650
Deferred costs, net 33,106 42,072
Lease right-of-use assets 49,640 56,917
Goodwill 439,877 436,029
Intangible assets, net 101,940 114,595
Deferred income taxes 5,097 14,100
Other long-term assets 25,127 17,878
Total assets 3,816,465 3,046,067
Current liabilities:    
Accounts payable 20,348 23,253
Accrued compensation and benefits 33,834 30,410
Accrued expenses and other current liabilities 36,109 30,982
Income tax payable 7,761 2,590
Deferred revenue 731,746 616,992
Lease liabilities 10,981 11,725
Total current liabilities 840,779 715,952
Deferred income taxes 2,216 1,835
Lease liabilities, noncurrent 43,607 51,393
Other long-term liabilities 18,226 10,567
Total liabilities 904,828 779,747
Commitments and contingencies (note 15)
Stockholders’ equity:    
Additional paid-in capital 1,196,547 965,670
Accumulated other comprehensive (loss) income (11,958) 992
Retained earnings 1,727,046 1,299,656
Total stockholders’ equity 2,911,637 2,266,320
Total liabilities and stockholders’ equity 3,816,465 3,046,067
Class A common stock    
Stockholders’ equity:    
Common stock 2 2
Class B common stock    
Stockholders’ equity:    
Common stock $ 0 $ 0
v3.22.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Allowance for doubtful accounts $ 473 $ 193
Class A common stock    
Common stock, par value (in usd per share) $ 0.00001 $ 0.00001
Common stock, shares authorized (in shares) 800,000,000 800,000,000
Common stock, shares issued (in shares) 139,432,822 137,062,817
Common stock, shares outstanding (in shares) 139,432,822 137,062,817
Class B common stock    
Common stock, par value (in usd per share) $ 0.00001 $ 0.00001
Common stock, shares authorized (in shares) 190,000,000 190,000,000
Common stock, shares issued (in shares) 14,763,775 14,993,991
Common stock, shares outstanding (in shares) 14,763,775 14,993,991
v3.22.1
Consolidated Statements of Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Revenues:      
Total revenues $ 1,850,777 $ 1,465,069 $ 1,104,081
Cost of revenues:      
Total cost of revenues [1] 503,678 408,928 303,369
Gross profit 1,347,099 1,056,141 800,712
Operating expenses:      
Research and development [1] 382,035 294,220 209,895
Sales and marketing [1] 288,061 235,014 190,331
General and administrative [1] 171,507 149,113 114,267
Total operating expenses [1] 841,603 678,347 514,493
Operating income 505,496 377,794 286,219
Other income, net 6,815 16,199 27,478
Income before income taxes 512,311 393,993 313,697
Provision for income taxes 84,921 13,995 12,579
Net income $ 427,390 $ 379,998 $ 301,118
Net income per share:      
Basic (in usd per share) $ 2.79 $ 2.52 $ 2.04
Diluted (in usd per share) $ 2.63 $ 2.36 $ 1.90
Weighted-average shares used to compute net income per share:      
Basic (in shares) 153,251 150,666 147,796
Diluted (in shares) 162,277 160,732 158,296
Other comprehensive income:      
Net change in unrealized (loss) gain on available-for-sale investments, net of tax $ (9,872) $ 985 $ 2,388
Net change in cumulative foreign currency translation loss (3,078) (453) (2,857)
Comprehensive income 414,440 380,530 300,649
Subscription services      
Revenues:      
Total revenues 1,483,976 1,179,486 896,294
Cost of revenues:      
Total cost of revenues [1] 224,911 184,589 136,328
Professional services and other      
Revenues:      
Total revenues 366,801 285,583 207,787
Cost of revenues:      
Total cost of revenues [1] $ 278,767 $ 224,339 $ 167,041
[1]
(1) Includes stock-based compensation as follows:
Cost of revenues:
Cost of subscription services$4,795 $4,840 $2,638 
Cost of professional services and other36,293 27,698 17,518 
Research and development83,837 63,541 37,001 
Sales and marketing56,830 40,574 27,537 
General and administrative52,881 48,348 31,212 
Total stock-based compensation$234,636 $185,001 $115,906 
v3.22.1
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Total stock-based compensation $ 234,636 $ 185,001 $ 115,906
Cost of subscription services      
Total stock-based compensation 4,795 4,840 2,638
Cost of professional services and other      
Total stock-based compensation 36,293 27,698 17,518
Research and development      
Total stock-based compensation 83,837 63,541 37,001
Sales and marketing      
Total stock-based compensation 56,830 40,574 27,537
General and administrative      
Total stock-based compensation $ 52,881 $ 48,348 $ 31,212
v3.22.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
[1]
Class A & B common stock
Additional paid-in capital
Retained earnings
Retained earnings
Cumulative Effect, Period of Adoption, Adjustment
[1]
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Jan. 31, 2019     146,190,079        
Beginning balance at Jan. 31, 2019 $ 1,237,749 $ (657) $ 1 $ 617,623 $ 619,197 $ (657) $ 928
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon exercise of stock options (in shares)     1,665,778        
Issuance of common stock upon    exercise of stock options 10,899     10,899      
Issuance of common stock upon vesting of restricted stock units (in shares)     1,239,726        
Replacement award value in connection with business combination 657            
Stock-based compensation expense 116,296     116,296      
Other comprehensive income (loss) (468)           (468)
Net income 301,118       301,118    
Ending balance (in shares) at Jan. 31, 2020     149,095,583        
Ending balance at Jan. 31, 2020 1,665,594   $ 1 745,475 919,658   460
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon exercise of stock options (in shares)     1,839,723        
Issuance of common stock upon    exercise of stock options 34,816   $ 1 34,815      
Issuance of common stock upon vesting of restricted stock units (in shares)     1,121,502        
Stock-based compensation expense 185,380     185,380      
Other comprehensive income (loss) 532           532
Net income 379,998       379,998    
Ending balance (in shares) at Jan. 31, 2021     152,056,808        
Ending balance at Jan. 31, 2021 $ 2,266,320   $ 2 965,670 1,299,656   992
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon exercise of stock options (in shares) 1,476,898   1,476,898        
Issuance of common stock upon    exercise of stock options $ 51,538     51,538      
Issuance of common stock upon vesting of restricted stock units (in shares)     854,536        
Shares withheld related to net share settlement (in shares) (191,645)            
Shares withheld related to net share settlement $ (56,398)            
Stock-based compensation expense 235,737     235,737      
Other comprehensive income (loss) (12,950)           (12,950)
Net income 427,390       427,390    
Ending balance (in shares) at Jan. 31, 2022     154,196,597        
Ending balance at Jan. 31, 2022 $ 2,911,637   $ 2 $ 1,196,547 $ 1,727,046   $ (11,958)
[1] (1) We adopted Accounting Standards Update (ASU) 2016-02, “Leases” (Topic 842) using the modified retrospective method as of February 1, 2019 and elected the transition option that allows us not to restate the comparative periods in our financial statements in the year of adoption.
v3.22.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Cash flows from operating activities      
Net income $ 427,390 $ 379,998 $ 301,118
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 27,448 29,455 19,859
Reduction of operating lease right-of-use assets 11,445 10,347 7,966
Amortization (accretion) of discount on short-term investments 6,264 3,134 (3,274)
Stock-based compensation 234,636 185,001 115,906
Amortization of deferred costs 26,050 20,677 20,521
Deferred income taxes 11,079 (1,048) (6,663)
Gain on foreign currency from mark-to-market derivative (782) (365) (120)
Bad debt expense (recovery) 272 (307) 244
Changes in operating assets and liabilities:      
Accounts receivable (67,020) (174,067) (55,531)
Unbilled accounts receivable (16,060) (14,387) (14,555)
Deferred costs (17,084) (27,164) (25,237)
Prepaid expenses and other current and long-term assets (2,910) (12,424) (2,700)
Accounts payable (2,997) 754 2,813
Accrued expenses and other current liabilities 9,439 13,889 (15,230)
Income taxes payable 5,275 (3,023) 1,131
Deferred revenue 116,144 147,479 97,753
Operating lease liabilities (11,607) (9,129) (7,480)
Other long-term liabilities 7,481 2,426 854
Net cash provided by operating activities 764,463 551,246 437,375
Cash flows from investing activities      
Purchases of short-term investments (1,117,076) (979,292) (752,518)
Maturities and sales of short-term investments 792,918 654,341 688,091
Acquisitions, net of cash and restricted cash acquired (7,780) 0 (448,162)
Long-term assets (14,214) (8,683) (4,321)
Net cash used in investing activities (346,152) (333,634) (516,910)
Cash flows from financing activities      
Changes in lease liabilities - finance leases (384) (1,039) (984)
Proceeds from exercise of common stock options 51,538 34,857 10,994
Taxes paid related to net share settlement of equity awards (55,294) 0 0
Net cash (used in) provided by financing activities (4,140) 33,818 10,010
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (4,657) 484 (2,856)
Net change in cash, cash equivalents, and restricted cash 409,514 251,914 (72,381)
Cash, cash equivalents, and restricted cash at beginning of period 731,711 479,797 552,178
Cash, cash equivalents, and restricted cash at end of period 1,141,225 731,711 479,797
Cash, cash equivalents, and restricted cash at end of period:      
Cash and cash equivalents 1,138,040 730,504 476,733
Restricted cash included in other long-term assets 3,185 1,207 3,064
Cash, cash equivalents, and restricted cash at end of period 1,141,225 731,711 479,797
Supplemental disclosures of other cash flow information:      
Cash paid for income taxes, net of refunds 58,627 18,096 14,289
Excess tax benefits from employee stock plans 56,172 80,661 50,411
Non-cash investing activities:      
Changes in accounts payable and accrued expenses related to property and equipment purchases $ (2,489) $ 3,165 $ 567
v3.22.1
Summary of Business and Significant Accounting Policies
12 Months Ended
Jan. 31, 2022
Accounting Policies [Abstract]  
Summary of Business and Significant Accounting Policies Summary of Business and Significant Accounting Policies
Description of Business
Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in other regulated industries, including, for example, consumer goods, chemicals, and cosmetics. Our fiscal year end is January 31.
Principles of Consolidation and Basis of Presentation
These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding annual financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:
the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations;
the determination of the period of benefit for amortization of deferred costs;
the realizability of deferred income tax assets and liabilities;
the fair value of our stock-based awards.
As future events cannot be determined with precision, actual results could differ significantly from those estimates.
Segment Information
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. We define the term “chief operating decision maker” to be our Chief Executive Officer. Our Chief Executive Officer reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the consolidated financial statements.
Revenue Recognition
We derive our revenues primarily from subscription services and professional services. Subscription services revenues consist of fees from customers accessing our cloud-based software solutions and fees for our data solutions. Professional services and other revenues consist primarily of fees from implementation services, configuration, data services, training, and managed services related to our solutions. Revenues are recognized when control of these services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services.
We determine revenue recognition through the following steps:
Identification of the contract, or contracts, with a customer;
Identification of the performance obligations in the contract;
Determination of the transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when, or as, we satisfy a performance obligation.
Our subscription services agreements are generally non-cancelable during the term, although customers typically have the right to terminate their agreements for cause in the event of material breach.
Subscription Services Revenues
Subscription services revenues are recognized ratably over the respective non-cancelable subscription term because of the continuous transfer of control to the customer. Our subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software.
Professional Services and Other Revenues
The majority of our professional services arrangements are billed on a time and materials basis and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain professional services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred. Data services and training revenues are generally recognized as the services are performed.
Contracts with Multiple Performance Obligations
Some of our contracts with customers contain multiple performance obligations. For these contracts, we account for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type and geography.
Deferred Costs
Deferred costs represents sales commissions associated with obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit that we have determined to be one to three years. We determined the period of benefit by taking into consideration the expected renewal period of our customer contracts, our technology and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income.
Certain Risks and Concentrations of Credit Risk
Our revenues are derived from subscription services, professional services and other services delivered primarily to the life sciences industry. We operate in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities, and other factors could negatively impact our future operating results.
Our financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and trade accounts receivable. Our cash equivalents and short-term investments are held by established financial institutions. We have established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these financial institutions may significantly exceed federally insured limits.
We do not require collateral from our customers and generally require payment within 30 days to 60 days of billing.
The following customers individually exceeded 10% of total accounts receivable as of the dates shown:
January 31,
20222021
Customer 110%12%
Customer 210%*
 * Does not exceed 10%.
No single customer represented over 10% of our total revenues for any of the years presented.
Cash Equivalents
We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Short-term Investments
Our short-term investments are classified as available-for-sale and recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. We evaluate our investments to assess whether those with unrealized loss positions are other than temporarily impaired. We consider impairments to be other than temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other than temporary are determined based on the specific identification method and are reported in other income, net, in the consolidated statements of comprehensive income. Interest, amortization of premiums, and accretion of discount on all short-term investments are also included as a component of other income, net, in the consolidated statements of comprehensive income.
We may sell our short-term investments at any time, without significant penalty, for use in current operations or for other purposes, even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond 12 months, as current assets in the accompanying consolidated balance sheets.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts, which is not material.
Property and Equipment
Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets and commences once the asset is placed in service or ready for its intended use. Land is not depreciated. The estimated useful lives by asset classification are as follows:
Building30 years
Land and building improvements10 years(land improvements) and estimated useful life of building (building improvements)
Equipment and computers3 years
Furniture and fixtures5 years
Leasehold improvementsShorter of remaining life of the lease term or estimated useful life
Leases
We have operating leases for corporate offices. Additionally, we are the sublessor for certain office space.
We adopted Accounting Standards Update (ASU) 2016-02 “Leases” (Topic 842) using the modified retrospective method as of February 1, 2019 with an immaterial amount of cumulative effect adjustment recorded to our retained earnings. Subsequent to our adoption of Topic 842, we recognize lease right-of-use assets and liabilities at the commencement date based on the present value of lease payments over the lease term. We use an estimate of our discount rate based on the information available at the lease commencement date in determining the present value of lease payments, unless the implicit rate is readily determinable. The lease right-of-use assets also include any lease payments made and exclude lease incentives such as tenant improvement allowances. Options to extend or terminate the lease are included in the lease term when it is reasonably certain that we will exercise the extension or termination option.
Our operating leases typically include non-lease components such as common-area maintenance costs. We have elected to exclude non-lease components from lease payments for the purpose of calculating lease right-of-use assets and liabilities and these are expensed as incurred as variable lease payments.
Leases with a term of one year or less are not recognized on our consolidated balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.
Internal-Use Software
We capitalize certain costs incurred for the development of computer software for internal use. We capitalize these costs during the development of the project, when it is determined that it is probable that the project will be completed and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training, and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life of three years, and the amortization expense is recorded as a component of cost of subscription services. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.
Goodwill and Intangible Assets
Goodwill is tested for impairment annually in the fourth quarter of each year or if circumstances indicate the carrying value of goodwill is impaired.
We have one reporting unit and evaluate goodwill for impairment at the entity level. We completed our annual impairment test in our fourth quarter of the fiscal year ended January 31, 2022, which resulted in no impairment of the goodwill balance.
All other intangible assets associated with purchased intangibles, consisting of existing technology, databases, customer relationships, software, trade names and trademarks, data supplier and partner relationships, non-competition agreements, brand, and backlog are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. Amortization expense related to existing technology, databases, data supplier and partner relationships, software, and backlog is included in cost of subscription services. Amortization expense related to customer relationships, trade names and trademarks, and brand are included in sales and marketing expense. Amortization expense related to non-competition agreements are included in both general and administrative and research and development expense.
Long-Lived Assets
Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
Business Combinations
The purchase price in a business combination is assigned to the estimated acquisition date fair values of the tangible and intangible assets acquired and the liabilities assumed with the residual recorded as goodwill. Critical estimates in valuing certain of the intangible assets include, but are not limited to, the net present value of future expected cash flows, future revenue growth, margins, customer retention rates, technology life, royalty rates, expected use of acquired assets, and discount rates.
Stock-based Compensation
We recognize compensation expense for all stock-based awards, including stock options and restricted stock units (RSUs), based on the estimate of fair value of the award at the grant date. The fair value of each option award is estimated on the grant date using either a Black-Scholes option-pricing model or a Monte Carlo simulation, to the extent market conditions exist, and a single option award approach. These models require that at the date of grant we determine the fair value of the underlying common stock, the expected term of the award, the expected volatility of the price of our common stock, risk-free interest rates, and expected dividend yield of our common stock. The fair value of each RSU award is measured based on the closing stock price of our common stock on the date of grant. We account for forfeitures as they occur. The compensation expense is recognized using a straight-line basis over the requisite service periods of the awards, which is one to five years for RSUs and four to nine years for stock options.
Cost of Revenues
Cost of subscription services revenues consists of expenses related to our computing infrastructure provided by third parties, including salesforce.com and Amazon Web Services, personnel-related costs associated with hosting our subscription services and providing support including our data stewards, data acquisition costs, and allocated overhead, amortization expense associated with capitalized internal-use software related to our subscription services, and amortization expense associated with purchased intangibles related to our subscription services. Cost of subscription services revenues for Veeva CRM and certain of our multichannel customer relationship management applications include fees paid to salesforce.com for our use of the Salesforce Platform and the associated hosting infrastructure and data center operations that are provided by salesforce.com.
Cost of professional services and other revenues consists primarily of employee-related expenses associated with providing these services, including salaries, benefits and stock-based compensation expense, the cost of third-party subcontractors, travel costs, and allocated overhead.
Advertising Expenses
Advertising expenditures are expensed as incurred and were immaterial for each of the years presented.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
We regularly assess the realizability of our deferred tax assets and establish a valuation allowance if it is more likely than not that some or all of our deferred tax assets will not be realized. We evaluate and weigh all available positive and negative evidence such as historic results, future reversals of existing deferred tax liabilities, projected future taxable income, as well as prudent and feasible tax-planning strategies. Generally, more weight is given to objectively verifiable evidence such as the cumulative income in recent years.
We establish liabilities or reduce assets for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that the position will be sustained upon an audit, including resolution of related appeals or litigation processes, if any. The second step requires us to measure the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. We recognize interest accrued and penalties related to unrecognized tax benefits as a component of provision for income taxes.
Foreign Currency Exchange
Adjustments resulting from translating financial statements for those entities that do not have U.S. dollars as their functional currency are recorded as part of a separate component of the consolidated statements of comprehensive income. All assets and liabilities denominated in currencies other than U.S. dollars are translated into the U.S. dollar functional currency at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign currency transaction gains and losses are included in the consolidated statements of comprehensive income for the period.
Indemnification
Our contracts generally include provisions for indemnifying customers against liabilities if our solutions infringe a third party’s intellectual property rights, and we may also incur liabilities if we breach the security and/or confidentiality obligations in our contracts. To date, we have not incurred any material costs, and we have not accrued any liabilities in the accompanying consolidated financial statements as a result of these obligations.
Loss Contingencies
Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
New Accounting Pronouncements Adopted in Fiscal 2022
Income Taxes
In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” which simplifies accounting guidance for certain tax matters. We adopted this standard effective February 1, 2021. The adoption of this new standard did not have a material impact on our consolidated financial statements.
v3.22.1
Acquisitions
12 Months Ended
Jan. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions Acquisitions
Crossix
On November 1, 2019, we acquired 100% ownership of Crossix in exchange for total consideration of $428 million, which includes the impact of adjustments to purchase price associated with the cash and net working capital of the acquired entity at close. In addition, we granted certain Crossix employees equity retention awards valued at approximately $120 million in the aggregate, which will be expensed as share-based compensation over the remaining service period. Crossix brings Veeva additional depth in patient data and data analytics. Crossix’s existing data analytics offerings are complementary to our existing Commercial Cloud offerings, and we are using the Crossix Data Platform to build our Veeva Data Cloud offerings.
The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands):
Useful lifeFair value
Net assets acquired$4,766 
Identifiable intangible assets:
Customer relationships10 years70,100 
Existing technology6 years19,200 
Trade name and trademarks5 years13,200 
Other intangibles1to7 years6,000 
Total purchased intangible assets108,500 
Goodwill314,642 
Total purchase consideration$427,908 
The following unaudited pro forma information presents the combined results of operations for the periods presented as if the acquisition had been completed on February 1, 2019, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include the amortization associated with estimates for the purchased intangible assets and stock-based compensation expense associated with the retention awards granted.
The unaudited pro forma results do not reflect any cost saving synergies from operating efficiencies or the effect of the incremental costs incurred in integrating the two companies. Accordingly, these unaudited pro forma results are presented for information purpose only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations (in thousands):
Fiscal Year Ended January 31,
2020
Pro forma revenues$1,153,497 
Pro forma net income$278,215 
Pro forma net income per share:
     Basic$1.88 
     Diluted$1.76 
Physicians World
On November 7, 2019, we completed our acquisition of Physicians World in exchange for total cash consideration of $41 million, which includes the impact of adjustments to purchase price associated with the cash and net working capital of the acquired entity at close. In addition, we granted certain Physicians World employees equity retention awards valued at approximately $15 million in the aggregate. The acquisition of Physicians World makes it easier for our customers to get industry leading cloud software and services from a single vendor. The legacy Physicians World business is now part of our Veeva Digital Events offerings. Pro forma results of operations have not been presented because the effect of this acquisition was not material to our consolidated financial statements.
The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands):
Useful lifeFair value
Net assets acquired$1,221 
Identifiable intangible assets:
Customer relationships10 years$7,700
Existing technology6 years3,300 
Trade name and trademarks5 years700 
Total purchased intangible assets11,700 
Goodwill28,083 
Total purchase consideration$41,004 
v3.22.1
Short-Term Investments
12 Months Ended
Jan. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Short-Term Investments Short-Term Investments
At January 31, 2022, short-term investments consisted of the following (in thousands):
Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Estimated
fair
value
Available-for-sale securities:
Certificates of deposits$13,500 $— $(15)$13,485 
Asset-backed securities191,676 45 (1,432)190,289 
Commercial paper29,432 — (2)29,430 
Corporate notes and bonds669,489 276 (5,856)663,909 
Foreign government bonds24,577 13 (179)24,411 
U.S. agency obligations27,978 12 (254)27,736 
U.S. treasury securities290,513 46 (1,755)288,804 
Total available-for-sale securities$1,247,165 $392 $(9,493)$1,238,064 
At January 31, 2021, short-term investments consisted of the following (in thousands):
Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Estimated
fair
value
Available-for-sale securities:
Certificates of deposits$17,350 $15 $(1)$17,364 
Asset-backed securities125,833 745 (2)126,576 
Commercial paper57,390 (2)57,396 
Corporate notes and bonds428,710 2,360 (23)431,047 
Foreign government bonds31,855 45 (2)31,898 
U.S. agency obligations52,756 119 — 52,875 
U.S. treasury securities215,379 587 — 215,966 
Total available-for-sale securities$929,273 $3,879 $(30)$933,122 
The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands):
January 31,
20222021
Due in one year or less$457,948 $428,155 
Due in greater than one year780,116 504,967 
Total short-term investments$1,238,064 $933,122 
We have not recorded an allowance for credit losses, as we believe any such losses would be immaterial based on the high credit quality of our investments. We intend to hold our securities to maturity and it is more likely than not we will hold these securities until recovery of the cost basis.
The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2022 (in thousands):
Held for less than 12 months
Fair
value
Gross
unrealized
losses
Certificates of deposits$5,985 $(15)
Asset-backed securities177,056 (1,432)
Commercial paper17,190 (2)
Corporate notes and bonds571,099 (5,856)
Foreign government bonds19,594 (179)
U.S. agency obligations24,725 (254)
U.S. treasury securities247,509 (1,756)
The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2021 (in thousands):
Held for less than 12 months
Fair
value
Gross
unrealized
losses
Certificates of deposits$3,749 $(2)
Asset-backed securities3,318 (1)
Commercial paper17,626 (2)
Corporate notes and bonds29,558 (23)
Foreign government bonds2,679 (2)
Asset values and gross unrealized losses of available-for-sale securities held for more than 12 months as of January 31, 2022 and 2021 were immaterial. There were no impairments considered other-than-temporary as of January 31, 2022 and 2021 as it is more likely than not we will hold these securities until recovery of the cost basis.
v3.22.1
Deferred Costs
12 Months Ended
Jan. 31, 2022
Deferred Costs [Abstract]  
Deferred Costs Deferred CostsDeferred costs, which consists of deferred sales commissions, were $33 million and $42 million as of January 31, 2022 and January 31, 2021, respectively. Amortization expense for the deferred costs included in sales and marketing expenses in the consolidated statements of comprehensive income was $26 million, $21 million, and $21 million for the fiscal years ended January 31, 2022, 2021, and 2020, respectively. There have been no impairment losses recorded in relation to the costs capitalized for any period presented.
v3.22.1
Property and Equipment, Net
12 Months Ended
Jan. 31, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net Property and Equipment, Net
Property and equipment, net consists of the following as of the dates shown (in thousands):
January 31,
20222021
Land$3,040 $3,040 
Building20,984 20,984 
Land improvements and building improvements22,392 22,392 
Equipment and computers3,581 8,847 
Furniture and fixtures15,040 13,452 
Leasehold improvements19,002 13,945 
Construction in progress730 606 
84,769 83,266 
Less accumulated depreciation(30,274)(29,616)
Total property and equipment, net$54,495 $53,650 
Total depreciation expense was $7 million, $9 million, and $9 million for the fiscal years ended January 31, 2022, 2021, and 2020, respectively. Land is not depreciated.
v3.22.1
Goodwill and Intangible Assets
12 Months Ended
Jan. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
Goodwill was $440 million and $436 million as of January 31, 2022 and January 31, 2021, respectively. The following schedule presents the details of goodwill as of January 31, 2022 (dollar amounts in thousands):
Balance as of January 31, 2020$438,529 
Purchase price goodwill reduction from Crossix tax adjustments(2,500)
Balance as of January 31, 2021436,029 
Goodwill from business acquisitions$3,848 
Balance as of January 31, 2022$439,877 
The following schedule presents the details of intangible assets as of January 31, 2022 (dollar amounts in thousands):
January 31, 2022
Gross
carrying
amount
Accumulated
amortization
Net
Remaining
useful life
(in years)
Existing technology$28,580 $(12,187)$16,393 3.9
Customer relationships113,157 (38,829)74,328 7.0
Trade name and trademarks13,900 (6,645)7,255 2.8
Other intangibles21,405 (17,441)3,964 3.8
Total intangible assets$177,042 $(75,102)$101,940 
The following schedule presents the details of intangible assets as of January 31, 2021 (dollar amounts in thousands):
January 31, 2021
Gross
carrying
amount
Accumulated
amortization
NetRemaining
useful life
(in years)
Existing technology$26,180 $(8,367)$17,813 4.8
Customer relationships110,643 (27,741)82,902 8.0
Trade name and trademarks13,900 (4,005)9,895 3.8
Other intangibles20,453 (16,468)3,985 5.1
Total intangible assets$171,176 $(56,581)$114,595 
Amortization expense associated with intangible assets was $19 million, $20 million, and $10 million for the fiscal years ended January 31, 2022, 2021, and 2020 respectively.
As of January 31, 2022, the estimated amortization expense for intangible assets, for the next five years and thereafter is as follows (in thousands):
Fiscal 2023$19,463 
Fiscal 202419,459 
Fiscal 202518,557 
Fiscal 202614,147 
Fiscal 20278,922 
Thereafter21,392 
Total$101,940 
v3.22.1
Accrued Expenses
12 Months Ended
Jan. 31, 2022
Payables and Accruals [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consisted of the following as of the dates shown (in thousands):
January 31,
20222021
Accrued commissions$8,556 $7,498 
Accrued bonus4,677 4,134 
Accrued vacation5,546 4,716 
Payroll tax payable9,487 10,250 
Accrued other compensation and benefits5,568 3,812 
Total accrued compensation and benefits$33,834 $30,410 
Accrued fees payable to salesforce.com$6,521 $6,381 
Taxes payable9,743 13,598 
Accrued third-party professional services subcontractors' fees1,961 1,515 
Other accrued expenses17,884 9,488 
Total accrued expenses and other current liabilities$36,109 $30,982 
v3.22.1
Fair Value Measurements
12 Months Ended
Jan. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The carrying amounts of accounts receivable and other current assets, accounts payable, and accrued liabilities approximate their fair value due to their short-term nature.
Financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:
Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability.
The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2022 (in thousands):
Level 1
Level 2
Total
Assets
Cash equivalents:
Money market funds$428,411 $— $428,411 
Corporate notes and bonds— 5,853 5,853 
Asset-backed securities— 2,568 2,568 
Short-term investments:
Certificates of deposits— 13,485 13,485 
Asset-backed securities— 190,289 190,289 
Commercial paper— 29,430 29,430 
Corporate notes and bonds— 663,909 663,909 
Foreign government bonds— 24,411 24,411 
U.S. agency obligations— 27,736 27,736 
U.S. Treasury securities— 288,804 288,804 
Foreign currency derivative contracts— 1,222 1,222 
Total financial assets$428,411 $1,247,707 $1,676,118 
The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2021 (in thousands):
Level 1
Level 2
Total
Assets
Cash equivalents:
Money market funds$259,937 $— $259,937 
U.S. Treasury securities— 15,520 15,520 
Short-term investments:
Certificates of deposits— 17,364 17,364 
Asset-backed securities— 126,576 126,576 
Commercial paper— 57,396 57,396 
Corporate notes and bonds— 431,047 431,047 
Foreign government bonds— 31,898 31,898 
U.S. agency obligations— 52,875 52,875 
U.S. Treasury securities— 215,966 215,966 
Foreign currency derivative contracts— 440 440 
Total financial assets$259,937 $949,082 $1,209,019 
Liabilities
Foreign currency derivative contracts$— $72 $72 
Total financial liabilities$— $72 $72 
We determine the fair value of our security holdings based on pricing from our service providers and market prices from industry-standard independent data providers. The valuation techniques used to measure the fair value of financial instruments having Level 2 inputs were derived from non-binding consensus prices that are corroborated by observable market data or quoted market prices for similar instruments. Such market prices may be quoted prices in active markets for identical assets (Level 1 inputs) or pricing determined using inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs).
Balance Sheet Hedges
We enter into foreign currency forward contracts in order to hedge our foreign currency exposure. We account for derivative instruments at fair value with changes in the fair value recorded as a component of other income, net, in our consolidated statements of comprehensive income. Cash flows from such forward contracts are classified as operating activities. The realized foreign currency gains and losses were not material for any of the fiscal years ended January 31, 2022, 2021, and 2020.
The fair value of our outstanding derivative instruments is summarized below (in thousands): 
January 31,
20222021
Notional amount of foreign currency derivative contracts$87,097 $52,516 
Fair value of foreign currency derivative contracts85,876 52,148 
Derivatives not designated as hedging instruments are presented as components of the following balance sheet items for the periods shown as follows (in thousands): 
January 31,
Balance sheet presentation20222021
Foreign currency derivative contracts - assetsPrepaid expenses and other current assets$1,222 $440 
Foreign currency derivative contracts - liabilitiesAccrued expenses— 72 
v3.22.1
Income Taxes
12 Months Ended
Jan. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of income before income taxes by U.S. and foreign jurisdictions were as follows for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
United States$487,962 $378,042 $305,339 
Foreign24,349 15,951 8,358 
Total$512,311 $393,993 $313,697 
The majority of our revenues from international sales are invoiced from and collected by our U.S. entity and recognized as a component of income before taxes in the United States as opposed to a foreign jurisdiction.
Provision for income taxes consisted of the following for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
Current provision:
Federal$53,426 $7,108 $11,143 
State12,580 4,763 4,695 
Foreign7,837 2,825 3,404 
Total current provision73,843 14,696 19,242 
Deferred provision:
Federal1,870 (816)(1,063)
State945 681 (517)
Foreign8,264 (566)(5,083)
Total deferred provision11,079 (701)(6,663)
Provision for income taxes$84,921 $13,995 $12,579 
Provision for income taxes differed from the amount computed by applying the federal statutory income tax rate of 21% for each of the fiscal years ended January 31, 2022, 2021, and 2020 to income before income taxes as a result of the following for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
Federal tax statutory tax rate$107,585 $82,739 $65,876 
State taxes11,035 4,401 3,035 
Tax credits(25,968)(24,617)(23,468)
Stock-based compensation(29,715)(54,488)(34,569)
Valuation allowance19,402 10,269 7,408 
Foreign derived intangible income deduction (FDII)(3,406)(5,134)(4,836)
Other(1)
5,988 825 (867)
Provision for income taxes$84,921 $13,995 $12,579 
(1) Prior period balances were adjusted to conform with current period presentation.
The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and liabilities related to the following (in thousands):
January 31,
20222021
Deferred tax assets:
Accruals and reserves$7,068 $13,494 
Capitalized expenditures10,477 — 
Stock-based compensation16,615 11,486 
Net operating loss carryforward21,850 29,318 
Tax credit carryforward34,725 29,624 
Lease liabilities13,813 15,932 
Other(1)
2,955 977 
Gross deferred tax assets107,503 100,831 
Valuation allowance(48,484)(31,318)
Total deferred tax assets59,019 69,513 
Deferred tax liabilities:
Intangible assets(31,200)(30,253)
Lease right-of-use assets(12,497)(14,438)
Deferred costs(1)
(10,552)(11,481)
Other(1)
(1,889)(1,076)
Total deferred tax liabilities(56,138)(57,248)
Net deferred tax assets$2,881 $12,265 
(1) Prior period balances were adjusted to conform with current period presentation.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The valuation allowance at the end of January 31, 2022 was primarily related to certain foreign and U.S. state deferred tax assets.
As of January 31, 2022, the net operating loss carryforwards for federal, state, and foreign income tax purposes were approximately $48 million, $69 million, and $31 million, respectively. The federal net operating losses do not expire, while the state and foreign net operating losses begin to expire in 2031 and 2026, respectively.
As of January 31, 2022, we had $54 million of California research and development tax credits available to offset future taxes which do not expire.
We evaluate tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. We classify unrecognized tax benefits that are not expected to result in payment or receipt of cash within one year as “other non-current liabilities” in the consolidated balance sheets. As of January 31, 2022, the total amount of gross
unrecognized tax benefits was $25 million, of which $14 million, if recognized, would favorably impact our effective tax rate. The aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
Beginning balance$18,628 $14,515 $12,597 
Increases related to tax positions taken during the prior period3,218 96 796 
Increases related to tax positions taken during the current period4,122 4,126 3,420 
Decreases related to tax positions taken during the prior period— (51)(128)
Audit settlements(195)— — 
Lapse of statute of limitations(532)(58)(2,170)
Ending balance$25,241 $18,628 $14,515 
Our policy is to classify interest and penalties associated with unrecognized tax benefits as a component of the provision for income taxes. Interest and penalties were not significant during fiscal year ended January 31, 2022.
We file tax returns in the United States for federal, California, and other states. Fiscal years ended January 31, 2017 and forward remain open to examination for federal income tax, and fiscal years ended January 31, 2018 and forward remain open to examination for California and other states. We file tax returns in multiple foreign jurisdictions. The fiscal years ended January 31, 2017 and forward remain open to examination in these foreign jurisdictions.
v3.22.1
Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable
12 Months Ended
Jan. 31, 2022
Revenue Recognition and Deferred Revenue [Abstract]  
Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable Deferred Revenue, Performance Obligations, and Unbilled Accounts ReceivableFrom the deferred revenue balance at the beginning of the respective periods, we recognized $605 million, $464 million, and $353 million of subscription services revenue during the fiscal years ended January 31, 2022, 2021, and 2020, respectively. Professional services revenue recognized in the same periods from the deferred revenue balances at the beginning of the respective periods was immaterial.
Transaction Price Allocated to the Remaining Performance Obligations
Transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. We applied the practical expedient in accordance with ASU 2014-09, “Revenue from Contracts with Customers” (Topic 606) to exclude the amounts related to professional services contracts as these contracts generally have a remaining duration of one year or less.
As of January 31, 2022, approximately $1,507 million of revenue is expected to be recognized from remaining performance obligations for subscription services contracts. We expect to recognize revenue on approximately 79% of these remaining performance obligations over the next 12 months, with the balance recognized thereafter.
Unbilled Accounts Receivable
Unbilled accounts receivable consists of (i) a receivable primarily for the revenue recognized for professional services performed but not yet billed, which was $28 million and $20 million as of January 31, 2022 and January 31, 2021, respectively, and (ii) a contract asset primarily for revenue recognized from non-cancelable, multi-year orders in which fees increase annually but for which we are not contractually able to invoice until a future period, which was $36 million and $27 million as of January 31, 2022 and January 31, 2021, respectively.
v3.22.1
Leases
12 Months Ended
Jan. 31, 2022
Leases [Abstract]  
Leases Leases
We have operating leases for corporate offices. Our leases have various expiration dates through 2030, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for the fiscal years ended January 31, 2022 and 2021 was immaterial.
For the fiscal years ended January 31, 2022, 2021, and 2020, our operating lease expense was $14 million, $13 million, and $8 million, respectively.
Supplemental cash flow information related to leases was as follows (in thousands):
Fiscal year ended January 31,
20222021
Cash paid for amounts included in the measurement of lease liabilities$13,800 $11,401 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases3,848 12,214 
Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):
January 31,
20222021
Lease right-of-use assets$49,640 $56,917 
Lease liabilities$10,981 $11,347 
Lease liabilities, noncurrent43,607 51,393 
Total operating lease liabilities$54,588 $62,740 
Weighted Average Remaining Lease Term6.0 years6.7 years
Weighted Average Discount Rate3.7 %3.8 %
As of January 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands):
Fiscal 2023$12,143 
Fiscal 202411,942 
Fiscal 20258,951 
Fiscal 20267,251 
Fiscal 20276,316 
Thereafter14,674 
Total operating lease payments61,277 
Less imputed interest6,689 
Total operating lease liabilities$54,588 
Leases Leases
We have operating leases for corporate offices. Our leases have various expiration dates through 2030, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for the fiscal years ended January 31, 2022 and 2021 was immaterial.
For the fiscal years ended January 31, 2022, 2021, and 2020, our operating lease expense was $14 million, $13 million, and $8 million, respectively.
Supplemental cash flow information related to leases was as follows (in thousands):
Fiscal year ended January 31,
20222021
Cash paid for amounts included in the measurement of lease liabilities$13,800 $11,401 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases3,848 12,214 
Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):
January 31,
20222021
Lease right-of-use assets$49,640 $56,917 
Lease liabilities$10,981 $11,347 
Lease liabilities, noncurrent43,607 51,393 
Total operating lease liabilities$54,588 $62,740 
Weighted Average Remaining Lease Term6.0 years6.7 years
Weighted Average Discount Rate3.7 %3.8 %
As of January 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands):
Fiscal 2023$12,143 
Fiscal 202411,942 
Fiscal 20258,951 
Fiscal 20267,251 
Fiscal 20276,316 
Thereafter14,674 
Total operating lease payments61,277 
Less imputed interest6,689 
Total operating lease liabilities$54,588 
v3.22.1
Stockholders' Equity
12 Months Ended
Jan. 31, 2022
Share-based Payment Arrangement [Abstract]  
Stockholders' Equity Stockholders’ Equity
Common Stock
In connection with our initial public offering in October 2013 (IPO), we amended our certificate of incorporation to provide for Class A common stock, Class B common stock, and preferred stock. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock and common stock were converted into shares of Class B common stock. As a result, following the IPO, we have two classes of authorized common stock: Class A common stock and Class B common stock.
As of January 31, 2022, we had 139,432,822 shares of Class A common stock and 14,763,775 shares of Class B common stock outstanding.
As of January 31, 2021, we had 137,062,817 shares of Class A common stock and 14,993,991 shares of Class B common stock outstanding.
Voting Rights
The holders of our Class B common stock are entitled to ten votes per share, and holders of our Class A common stock are entitled to one vote per share. The holders of our Class A common stock and Class B common stock vote together as a single class, unless otherwise required by our restated certificate of incorporation or by law. Delaware
law could require either holders of our Class A common stock or our Class B common stock to vote separately as a single class in the following circumstances:
if we were to seek to amend our restated certificate of incorporation to increase the authorized number of shares of a class of stock, or to increase or decrease the par value of a class of stock, then that class would be required to vote separately to approve the proposed amendment; and
if we were to seek to amend our restated certificate of incorporation in a manner that alters or changes the powers, preferences, or special rights of a class of stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment.
Our restated certificate of incorporation requires the approval of a majority of our outstanding Class B common stock voting as a separate class for any transaction that would result in a change in control of our company.
Dividend Rights
Holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine. To date, no dividends have been declared or paid by us.
No Preemptive or Similar Rights
Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption, or sinking fund provisions.
Right to Receive Liquidation Distributions
Upon our dissolution, liquidation, or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.
Conversion Rights
Each outstanding share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. In addition, each share of Class B common stock will convert automatically into one share of Class A common stock upon any transfer, whether or not for value, which occurs following the closing of our IPO, except for certain permitted transfers described in our restated certificate of incorporation, including transfers to any “permitted transferee” as defined in our restated certificate of incorporation, which includes, among others, transfers:
to trusts, corporations, limited liability companies, partnerships, foundations or similar entities established by a Class B stockholder, provided that:
such transfer is to entities established by a Class B stockholder where the Class B stockholder retains the exclusive right to vote and direct the disposition of the shares of Class B common stock; or
such transfer does not involve payment of cash, securities, property, or other consideration to the Class B stockholder.
Once converted into Class A common stock, a share of Class B common stock may not be reissued.
All the outstanding shares of Class A and Class B common stock will convert automatically into shares of a single class of common stock upon the earliest to occur of the following: (i) upon the election of the holders of a majority of the then-outstanding shares of Class B common stock or (ii) October 15, 2023. Following such conversion, each share of common stock will have one vote per share and the rights of the holders of all outstanding common stock will be identical. Once converted into a single class of common stock, the Class A and Class B common stock may not be reissued.
Employee Equity Plans
Beginning in the fiscal quarter ended April 30, 2019, we implemented a new equity compensation program applicable to the vast majority of our employees but not applicable to our Chief Executive Officer (CEO). Prior to the adoption of the new equity compensation program, at the time of hire, our employees received a grant of RSUs that vested quarterly over 4 years and received additional equity from time to time thereafter. Under the new equity compensation program, the vast majority of our employees are granted both RSUs, which typically vest over a one-year period, and stock options, which typically vest over a four-year period.
2007 Stock Plan
Our board of directors adopted our 2007 Stock Plan (2007 Plan) in February 2007, and our stockholders approved it in February 2007. No further awards have been made under our 2007 Plan since the adoption of the 2012 Equity Incentive Plan. However, awards outstanding under our 2007 Plan will continue to be governed by their existing terms.

2012 Equity Incentive Plan
Our board of directors adopted our 2012 Equity Incentive Plan (2012 EIP) in November 2012, and our stockholders approved it in December 2012. An amendment and restatement of the 2012 EIP was approved by our board of directors in March 2013, and our stockholders approved it in March 2013. The 2012 EIP became effective on adoption and replaced our 2007 Plan. No further awards have been made under our 2012 EIP since the adoption of the 2013 Equity Incentive Plan. However, awards outstanding under the 2012 EIP will continue to be governed by their existing terms.
2013 Equity Incentive Plan
Our board of directors adopted our 2013 Equity Incentive Plan (2013 EIP) in August 2013, and our stockholders approved it in September 2013. The 2013 EIP became effective immediately on adoption although no awards were made under it until the date of our IPO on October 15, 2013, at which time our 2013 EIP replaced our 2012 EIP.
As of January 31, 2022, the number of shares of our Class A common stock available for issuance under the 2013 EIP was 38,720,277 plus any shares of our Class B common stock subject to awards under the 2012 EIP and the 2007 Plan that expire or lapse unexercised or, with respect to shares issued pursuant to such awards, are forfeited or repurchased by us after the date of our IPO on October 15, 2013. The number of shares available for issuance under the 2013 EIP automatically increases on the first business day of each of our fiscal years, commencing in 2014, by a number equal to the least of (a) 13.75 million shares, (b) 5% of the shares of all classes of our common stock outstanding on the last business day of the prior fiscal year, or (c) the number of shares determined by our board of directors. During our fiscal year ended January 31, 2022, our board of directors determined to add 6,082,272 shares of common stock to the 2013 EIP.
2013 Employee Stock Purchase Plan
Our Employee Stock Purchase Plan (ESPP) was adopted by our board of directors in August 2013 and our stockholders approved it in September 2013. The ESPP became effective as of our IPO registration statement on Form S-1, on October 15, 2013. Our ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986, as amended (Code). The ESPP was approved with a reserve of 4 million shares of Class A common stock for future issuance under various terms provided for in the ESPP. As of January 31, 2022, the number of shares available for issuance under our ESPP was 4,897,856. The number of shares available for issuance under the ESPP automatically increases on the first business day of each of our fiscal years, commencing in 2014, by a number equal to the least of (a) 2.2 million shares, (b) 1% of the shares of all classes of our common stock outstanding on the last business day of the prior fiscal year or (c) the number of shares determined by our board of directors. During our fiscal year ended January 31, 2022, our board of directors determined no additional shares were to be made available for issuance under the ESPP.
During active offering periods, our ESPP permits eligible employees to acquire shares of our common stock at 85% of the lower of the fair market value of our Class A common stock on the first day of the applicable offering period or the fair market value of our Class A common stock on the purchase date. Participants may purchase shares of common stock through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The initial offering period for our ESPP commenced on the date of our initial public offering and ended on June 15, 2014. We have not had any open offering periods subsequent to the initial offering period.
Stock Option Activity
The 2007 Stock Plan and the 2012 EIP provided, and the 2013 EIP provides, for the issuance of incentive and nonstatutory options to employees, consultants and non-employee directors. Options issued under and outside of the 2007 Plan generally are exercisable for periods not to exceed 10 years and generally vest over four to five years. Options issued under the 2012 EIP and 2013 EIP generally are exercisable for periods not to exceed 10 years and generally vest over four years, with certain options vesting over five to nine years. A summary of stock option activity for the fiscal year ended January 31, 2022 is as follows: 
Number
of shares
Weighted
average
exercise
price
Weighted
average
remaining
contractual
term (in years)
Aggregate
intrinsic
value
(in millions)
Options outstanding at January 31, 202112,761,289 $57.48 5.0$2,794 
Options granted1,155,396 277.06 
Options exercised(1,476,898)34.90 
Options forfeited/cancelled(349,265)172.64 
Options outstanding at January 31, 202212,090,522 $77.89 4.6$1,964 
Options vested and exercisable at January 31, 20227,203,834 $32.35 2.8$1,472 
Options vested and exercisable at January 31, 2022 and expected to vest thereafter12,090,522 $77.89 4.6$1,964 
The options granted during the fiscal year ended January 31, 2022 were predominantly made in connection with our annual performance review cycle. The weighted average grant-date fair value of options granted was $108.42, $71.86, and $60.05 for the fiscal years ended January 31, 2022, 2021, and 2020, respectively.
As of January 31, 2022, there was $229 million in unrecognized compensation cost related to unvested stock options granted under the 2012 Equity Incentive Plan and 2013 Equity Incentive Plan. This cost is expected to be recognized over a weighted average period of 2.6 years.
As of January 31, 2022, we had authorized and unissued shares of common stock sufficient to satisfy exercises of stock options.
Our closing stock price as reported on the New York Stock Exchange as of January 31, 2022, the last trading day of fiscal year 2022 was $236.54. The total intrinsic value of options exercised was approximately $363 million for the fiscal year ended January 31, 2022.
Stock Option Valuation Assumptions
The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented:
Fiscal year ended January 31,
202220212020
Volatility37%-39%39%-42%39%-41%
Expected term (in years)6.256.25-7.255.64-6.61
Risk-free interest rate0.70%-1.60%0.33%-1.43%1.39%-2.52%
Dividend yield—%—%—%
Restricted Stock Units
The 2013 EIP provides for the issuance of RSUs to employees. RSUs issued under the 2013 EIP generally vest over one to five years. A summary of RSU activity for the fiscal year ended January 31, 2022 is as follows:
Unreleased restricted
stock units
Weighted 
average grant
date fair value
Balance at January 31, 20211,032,215 $121.98 
RSUs granted518,172 277.79 
RSUs vested(854,536)173.01 
RSUs forfeited / cancelled(76,463)175.88 
Balance at January 31, 2022619,388 175.23 
As of January 31, 2022, there was a total of $90 million in unrecognized compensation cost related to unvested RSUs. This cost is expected to be recognized over a weighted-average period of approximately 1.2 years. The total intrinsic value of RSUs vested was $246 million for the fiscal year ended January 31, 2022.
v3.22.1
Other Income
12 Months Ended
Jan. 31, 2022
Other Income and Expenses [Abstract]  
Other Income Other Income
Other income, net, consisted of the following (in thousands):
Fiscal year ended January 31,
202220212020
Foreign currency (loss) gain$(714)$2,275 $(708)
(Amortization) accretion on investments(7,201)(3,082)3,001 
Interest income, net14,730 15,859 25,185 
Miscellaneous income— 1,147 — 
Other income, net$6,815 $16,199 $27,478 
v3.22.1
Net Income per Share
12 Months Ended
Jan. 31, 2022
Earnings Per Share [Abstract]  
Net Income per Share Net Income per Share
Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period.
Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method.
The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares.
The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data):
Fiscal year ended January 31,
202220212020
Class AClass BClass AClass BClass AClass B
Basic
Numerator
Net income, basic$386,180 $41,210 $341,866 $38,132 $266,104 $35,014 
Denominator
Weighted average shares used in computing net income per share, basic138,474 14,777 135,547 15,119 130,610 17,186 
Net income per share, basic$2.79 $2.79 $2.52 $2.52 $2.04 $2.04 
Diluted
Numerator
Net income, basic$386,180 $41,210 $341,866 $38,132 $266,104 $35,014 
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic41,210 — 38,132 — 35,014 — 
Reallocation of net income to Class B common stock— 21,480 — 21,409 — 17,652 
Net income, diluted$427,390 $62,690 $379,998 $59,541 $301,118 $52,666 
Denominator
Number of shares used for basic net income per share computation138,474 14,777 135,547 15,119 130,610 17,186 
Conversion of Class B to Class A common stock14,777 — 15,119 — 17,186 — 
Effect of potentially dilutive common shares9,026 9,026 10,066 10,066 10,500 10,500 
Weighted average shares used in computing net income per share, diluted162,277 23,803 160,732 25,185 158,296 27,686 
Net income per share, diluted$2.63 $2.63 $2.36 $2.36 $1.90 $1.90 
Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows:
Fiscal year ended January 31,
202220212020
Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive958,476 1,045,222 1,461,255 
v3.22.1
Commitments and Contingencies
12 Months Ended
Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Litigation
IQVIA Litigation Matters
Veeva OpenData and Veeva Network Action.
On January 10, 2017, IQVIA Inc. (formerly Quintiles IMS Incorporated) and IMS Software Services, Ltd. (collectively, “IQVIA”) filed a complaint against us in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:17-cv-00177)) (OpenData and Network Action). In the complaint, IQVIA alleges that we used unauthorized access to proprietary IQVIA data to improve our software and data products and that our software is designed to steal IQVIA trade secrets. IQVIA further alleges that we have intentionally gained unauthorized access to IQVIA proprietary information to gain an unfair advantage in marketing our products and that we have made false statements concerning IQVIA’s conduct and our data security capabilities. IQVIA asserts claims under both federal and state misappropriation of trade secret laws, federal false advertising law, and common law claims for unjust enrichment, tortious interference, and unfair trade practices. The complaint seeks declaratory and injunctive relief and unspecified monetary damages.
On March 13, 2017, we filed our answer denying IQVIA's claims and filed counterclaims. Our counterclaims allege that IQVIA, as the dominant provider of data for life sciences companies, has abused monopoly power to exclude Veeva OpenData and Veeva Network from their respective markets. The counterclaims allege that IQVIA has engaged in various tactics to prevent customers from using our applications and has deliberately raised costs and increased the difficulty of attempting to switch from IQVIA data to our data products. As amended, our counterclaims assert federal and state antitrust claims, as well as claims under California’s Unfair Practices Act and common law claims for intentional interference with contractual relations, intentional interference with prospective economic advantage, and negligent misrepresentation. The counterclaims seek injunctive relief, monetary damages exceeding $200 million, and attorneys’ fees. On October 3, 2018, the court denied IQVIA’s motion to dismiss our antitrust claims.
On February 18, 2020, IQVIA filed a motion for sanctions against Veeva, seeking default judgment and dismissal and, in the alternative, an adverse inference at trial related to discovery disputes. On May 7, 2021, the special master appointed to oversee litigation discovery ruled against IQVIA’s request for default judgment and dismissal and ruled in IQVIA’s favor with respect to certain other matters, including recommending to the trial judge that a permissive adverse inference instruction be issued to the jury with respect to certain documents that were not preserved by Veeva. Should the trial judge accept the recommendation, the jury would be permitted, but not required, to infer that certain evidence not preserved by Veeva would have been unfavorable to Veeva, if the jury first concludes that Veeva controlled the evidence, that the evidence was relevant, and that Veeva should have preserved the evidence. The jury is also likely to be instructed that it may also consider whether the non-preserved evidence was duplicative of other evidence produced by Veeva and whether Veeva’s conduct was reasonable in light of all circumstances. Veeva was also ordered to pay IQVIA’s fees and expenses incurred in connection with portions of its sanctions motion. On June 4, 2021, we appealed the special master’s ruling and IQVIA’s fee award to the federal district court judge.
Fact discovery is largely complete and we expect to complete expert discovery by November 2022.While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, and we are unable to make a meaningful estimate of the amount or range of gain or loss, if any, that could result from the OpenData and Network Action, we believe that IQVIA’s claims lack merit and that our counterclaims warrant injunctive relief and monetary damages for Veeva.
Veeva Nitro Action.
On July 17, 2019, IQVIA filed a lawsuit in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:19-cv-15517)) (IQVIA Declaratory Action) seeking a declaratory judgment that IQVIA is not liable to Veeva for disallowing use of IQVIA’s data products in Veeva Nitro or any later-introduced Veeva software products. The IQVIA Declaratory Action does not seek any monetary relief.
On July 18, 2019, we filed a lawsuit against IQVIA in the U.S. District Court for the Northern District of California (Veeva Systems Inc. v. IQVIA Inc. (No. 3:19-cv-04137)) (Veeva Nitro Action), alleging that IQVIA engaged in anticompetitive conduct as to Veeva Nitro. Our complaint asserts federal and state antitrust claims, as well as claims under California’s Unfair Competition Law and common law claims for intentional interference with contractual relations and intentional interference with prospective economic advantage. The complaint seeks injunctive relief and monetary damages. IQVIA filed its answer and affirmative defenses on September 5, 2019.
On September 26, 2019, the Northern District of California transferred the Veeva Nitro Action to the District of New Jersey (Veeva Systems Inc. v. IQVIA Inc. (No. 2:19-cv-18558)).
On March 24, 2020, we amended our complaint in the Veeva Nitro Action to include allegations of IQVIA’s anticompetitive conduct as to additional Veeva software applications, such as Veeva Andi, Veeva Align, and Veeva Vault MedComms; additional examples of IQVIA’s monopolistic behavior against Veeva Nitro; IQVIA’s unlawful access of Veeva’s proprietary software products; and a request for declaratory relief. IQVIA answered the amended complaint on May 22, 2020.
On August 21, 2020, the District of New Jersey consolidated the Veeva Nitro Action and IQVIA Declaratory Action, and stayed both actions pending conclusion of the OpenData and Network Action. On September 21, 2021, the court lifted the stay. We expect to complete fact discovery by June 2022, and to complete expert discovery by November 2022.
On March 22, 2022, IQVIA submitted a letter seeking permission to file a motion for partial judgment on the pleadings under Federal Rule of Civil Procedure 12(c). If filed, the motion would seek judgment against Veeva on four of five federal antitrust claims and the common law claim for intentional interference with contractual relations. The court has not ruled on IQVIA's request.
While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, we believe that our claims warrant injunctive and declaratory relief and monetary damages for Veeva and against IQVIA.
Fee Arrangements Related to the IQVIA Litigation Matters. We have entered into partial contingency fee arrangements with certain law firms representing us in the IQVIA litigations. Pursuant to those arrangements, such law firms are entitled to an agreed portion of any damages we recover from IQVIA (Contingency Fees) or may be entitled to payment of additional fees from us based on the achievement of certain outcomes (Success Fees). While it is reasonably possible that we may incur such Success Fees, we are unable to make an estimate of any such liability and have not accrued any liability related to Success Fees at this time.
Medidata Litigation Matter
On January 26, 2017, Medidata Solutions, Inc. filed a complaint in the U.S. District Court for the Southern District of New York (Medidata Solutions, Inc. v. Veeva Systems Inc. et al. (No. 1:17-cv-00589)) against us and five individual Veeva employees who previously worked for Medidata (“Individual Employees”). The complaint alleged that we induced and conspired with the Individual Employees to breach their employment agreements, including non-compete and confidentiality provisions, and to misappropriate Medidata’s confidential and trade secret information. The complaint sought declaratory and injunctive relief, unspecified monetary damages, and attorneys’ fees. Medidata has since amended its complaint twice, asserting the same claims with additional factual allegations, and has voluntarily dismissed the Individual Defendants without prejudice.
Fact discovery is now completed. On April 24, 2020, Medidata filed a motion for partial summary judgment on its claims for trade secret misappropriation as well as several of Veeva’s affirmative defenses. On May 15, 2020, we filed a motion for summary judgment on all of Medidata’s claims. On February 9, 2021, the court issued its ruling granting summary judgment in favor of Veeva as to certain of Medidata's claims and in favor of Medidata as to certain of Veeva's affirmative defenses. The trial in this matter is currently set for July 18, 2022. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, and we are unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome, we believe that Medidata’s claims lack merit.
Other Litigation Matters
From time to time, we may be involved in other legal proceedings and subject to claims incident to the ordinary course of business. Although the results of such legal proceedings and claims cannot be predicted with certainty, we believe we are not currently a party to any other legal proceedings, the outcome of which, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial position. Regardless of the outcome, such proceedings can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.
v3.22.1
Revenues by Product
12 Months Ended
Jan. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenues by Product Revenues by Product
Prior to the fiscal quarter ended October 31, 2021, we grouped our revenues into two product areas: Commercial Cloud and Vault. During the fiscal quarter ended October 31, 2021, we changed the product areas under which we group revenues to Commercial Solutions and R&D Solutions to better align with how we manage our business and to reflect the principal functions served by our products. Commercial Solutions consist of our cloud software, data, and analytics products built specifically to more efficiently and effectively commercialize our customers’ products. R&D Solutions consist of our clinical, quality, regulatory, and safety products. Specifically, revenues attributable to Vault PromoMats and Vault MedComms, applications used for commercial operations, are now reflected in Commercial Solutions.
The prior period revenue balances in the table below have been adjusted to reflect the current period presentation of our product areas. There were no changes to the aggregate amounts reported within our consolidated statements of comprehensive income.
Total revenues consist of the following (in thousands):
Fiscal year ended January 31,
202220212020
Subscription services
Commercial Solutions$876,458 $744,856 $593,562 
R&D Solutions607,518 434,630 302,732 
Total subscription services1,483,976 1,179,486 896,294 
Professional services
Commercial Solutions165,086 142,003 103,825 
R&D Solutions201,715 143,580 103,962 
Total professional services366,801 285,583 207,787 
Total revenues$1,850,777 $1,465,069 $1,104,081 
v3.22.1
Information about Geographic Areas
12 Months Ended
Jan. 31, 2022
Segment Reporting [Abstract]  
Information about Geographic Areas Information about Geographic Areas
We track and allocate revenues by principal geographic area rather than by individual country, which makes it impractical to disclose revenues for the United States or other specific foreign countries. We measure subscription services revenue primarily by the estimated location of the end users in each geographic area for our Commercial Solutions and primarily by the estimated location of usage in each geographic area for our R&D Solutions. We measure professional services revenue primarily by the location of the resources performing the professional services.
Total revenues by geographic area were as follows for the periods shown below (in thousands):
Fiscal year ended January 31,
202220212020
North America$1,063,770 $838,192 $607,704 
Europe509,127 400,790 310,215 
Asia Pacific225,968 183,848 151,052 
Middle East, Africa, and Latin America51,912 42,239 35,110 
Total revenues$1,850,777 $1,465,069 $1,104,081 
Long-lived assets by geographic area are as follows as of the periods shown below (in thousands):
January 31,
20222021
North America$45,625 $46,285 
Europe6,135 5,525 
Asia Pacific1,335 1,359 
Middle East, Africa, and Latin America1,400 481 
Total long-lived assets$54,495 $53,650 
v3.22.1
401(k) Plan
12 Months Ended
Jan. 31, 2022
Retirement Benefits [Abstract]  
401(k) Plan 401(k) PlanWe have a qualified defined contribution plan under Section 401(k) of the Internal Revenue Code covering eligible employees as well as a Registered Retirement Savings Plan (RRSP) for eligible employees in Canada. Under the 401(k) plan, we match up to $2,000 per employee per year. Under the RRSP plan, we also match up to $2,000 per employee per year. For the fiscal years ended January 31, 2022, 2021, and 2020, total expense related to these plans was $7 million, $6 million, and $4 million, respectively.
v3.22.1
Summary of Business and Significant Accounting Policies (Policies)
12 Months Ended
Jan. 31, 2022
Accounting Policies [Abstract]  
Description of Business
Description of Business
Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in other regulated industries, including, for example, consumer goods, chemicals, and cosmetics. Our fiscal year end is January 31.
Principles of Consolidation and Basis of Presentation
Principles of Consolidation and Basis of Presentation
These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding annual financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:
the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations;
the determination of the period of benefit for amortization of deferred costs;
the realizability of deferred income tax assets and liabilities;
the fair value of our stock-based awards.
As future events cannot be determined with precision, actual results could differ significantly from those estimates.
Segment Information
Segment Information
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. We define the term “chief operating decision maker” to be our Chief Executive Officer. Our Chief Executive Officer reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the consolidated financial statements.
Revenue Recognition
Revenue Recognition
We derive our revenues primarily from subscription services and professional services. Subscription services revenues consist of fees from customers accessing our cloud-based software solutions and fees for our data solutions. Professional services and other revenues consist primarily of fees from implementation services, configuration, data services, training, and managed services related to our solutions. Revenues are recognized when control of these services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services.
We determine revenue recognition through the following steps:
Identification of the contract, or contracts, with a customer;
Identification of the performance obligations in the contract;
Determination of the transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when, or as, we satisfy a performance obligation.
Our subscription services agreements are generally non-cancelable during the term, although customers typically have the right to terminate their agreements for cause in the event of material breach.
Subscription Services Revenues
Subscription services revenues are recognized ratably over the respective non-cancelable subscription term because of the continuous transfer of control to the customer. Our subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software.
Professional Services and Other Revenues
The majority of our professional services arrangements are billed on a time and materials basis and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain professional services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred. Data services and training revenues are generally recognized as the services are performed.
Contracts with Multiple Performance Obligations
Some of our contracts with customers contain multiple performance obligations. For these contracts, we account for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type and geography.
Deferred Costs
Deferred Costs
Deferred costs represents sales commissions associated with obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit that we have determined to be one to three years. We determined the period of benefit by taking into consideration the expected renewal period of our customer contracts, our technology and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income.
Certain Risks and Concentrations of Credit Risk
Certain Risks and Concentrations of Credit Risk
Our revenues are derived from subscription services, professional services and other services delivered primarily to the life sciences industry. We operate in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities, and other factors could negatively impact our future operating results.
Our financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and trade accounts receivable. Our cash equivalents and short-term investments are held by established financial institutions. We have established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these financial institutions may significantly exceed federally insured limits.
We do not require collateral from our customers and generally require payment within 30 days to 60 days of billing.
Cash Equivalents
Cash Equivalents
We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Short-term Investments
Short-term Investments
Our short-term investments are classified as available-for-sale and recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. We evaluate our investments to assess whether those with unrealized loss positions are other than temporarily impaired. We consider impairments to be other than temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other than temporary are determined based on the specific identification method and are reported in other income, net, in the consolidated statements of comprehensive income. Interest, amortization of premiums, and accretion of discount on all short-term investments are also included as a component of other income, net, in the consolidated statements of comprehensive income.
We may sell our short-term investments at any time, without significant penalty, for use in current operations or for other purposes, even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond 12 months, as current assets in the accompanying consolidated balance sheets.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts, which is not material.
Property and Equipment Property and EquipmentProperty and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets and commences once the asset is placed in service or ready for its intended use. Land is not depreciated.
Leases
Leases
We have operating leases for corporate offices. Additionally, we are the sublessor for certain office space.
We adopted Accounting Standards Update (ASU) 2016-02 “Leases” (Topic 842) using the modified retrospective method as of February 1, 2019 with an immaterial amount of cumulative effect adjustment recorded to our retained earnings. Subsequent to our adoption of Topic 842, we recognize lease right-of-use assets and liabilities at the commencement date based on the present value of lease payments over the lease term. We use an estimate of our discount rate based on the information available at the lease commencement date in determining the present value of lease payments, unless the implicit rate is readily determinable. The lease right-of-use assets also include any lease payments made and exclude lease incentives such as tenant improvement allowances. Options to extend or terminate the lease are included in the lease term when it is reasonably certain that we will exercise the extension or termination option.
Our operating leases typically include non-lease components such as common-area maintenance costs. We have elected to exclude non-lease components from lease payments for the purpose of calculating lease right-of-use assets and liabilities and these are expensed as incurred as variable lease payments.
Leases with a term of one year or less are not recognized on our consolidated balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.
Internal-Use Software
Internal-Use Software
We capitalize certain costs incurred for the development of computer software for internal use. We capitalize these costs during the development of the project, when it is determined that it is probable that the project will be completed and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training, and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life of three years, and the amortization expense is recorded as a component of cost of subscription services. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.
Goodwill and Intangible Assets
Goodwill and Intangible Assets
Goodwill is tested for impairment annually in the fourth quarter of each year or if circumstances indicate the carrying value of goodwill is impaired.
We have one reporting unit and evaluate goodwill for impairment at the entity level. We completed our annual impairment test in our fourth quarter of the fiscal year ended January 31, 2022, which resulted in no impairment of the goodwill balance.
All other intangible assets associated with purchased intangibles, consisting of existing technology, databases, customer relationships, software, trade names and trademarks, data supplier and partner relationships, non-competition agreements, brand, and backlog are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. Amortization expense related to existing technology, databases, data supplier and partner relationships, software, and backlog is included in cost of subscription services. Amortization expense related to customer relationships, trade names and trademarks, and brand are included in sales and marketing expense. Amortization expense related to non-competition agreements are included in both general and administrative and research and development expense.
Long-Lived Assets
Long-Lived Assets
Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
Business Combinations
Business Combinations
The purchase price in a business combination is assigned to the estimated acquisition date fair values of the tangible and intangible assets acquired and the liabilities assumed with the residual recorded as goodwill. Critical estimates in valuing certain of the intangible assets include, but are not limited to, the net present value of future expected cash flows, future revenue growth, margins, customer retention rates, technology life, royalty rates, expected use of acquired assets, and discount rates.
Stock-based Compensation
Stock-based Compensation
We recognize compensation expense for all stock-based awards, including stock options and restricted stock units (RSUs), based on the estimate of fair value of the award at the grant date. The fair value of each option award is estimated on the grant date using either a Black-Scholes option-pricing model or a Monte Carlo simulation, to the extent market conditions exist, and a single option award approach. These models require that at the date of grant we determine the fair value of the underlying common stock, the expected term of the award, the expected volatility of the price of our common stock, risk-free interest rates, and expected dividend yield of our common stock. The fair value of each RSU award is measured based on the closing stock price of our common stock on the date of grant. We account for forfeitures as they occur. The compensation expense is recognized using a straight-line basis over the requisite service periods of the awards, which is one to five years for RSUs and four to nine years for stock options.
Cost of Revenues
Cost of Revenues
Cost of subscription services revenues consists of expenses related to our computing infrastructure provided by third parties, including salesforce.com and Amazon Web Services, personnel-related costs associated with hosting our subscription services and providing support including our data stewards, data acquisition costs, and allocated overhead, amortization expense associated with capitalized internal-use software related to our subscription services, and amortization expense associated with purchased intangibles related to our subscription services. Cost of subscription services revenues for Veeva CRM and certain of our multichannel customer relationship management applications include fees paid to salesforce.com for our use of the Salesforce Platform and the associated hosting infrastructure and data center operations that are provided by salesforce.com.
Cost of professional services and other revenues consists primarily of employee-related expenses associated with providing these services, including salaries, benefits and stock-based compensation expense, the cost of third-party subcontractors, travel costs, and allocated overhead.
Advertising Expenses
Advertising Expenses
Advertising expenditures are expensed as incurred and were immaterial for each of the years presented.
Income Taxes
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
We regularly assess the realizability of our deferred tax assets and establish a valuation allowance if it is more likely than not that some or all of our deferred tax assets will not be realized. We evaluate and weigh all available positive and negative evidence such as historic results, future reversals of existing deferred tax liabilities, projected future taxable income, as well as prudent and feasible tax-planning strategies. Generally, more weight is given to objectively verifiable evidence such as the cumulative income in recent years.
We establish liabilities or reduce assets for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that the position will be sustained upon an audit, including resolution of related appeals or litigation processes, if any. The second step requires us to measure the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. We recognize interest accrued and penalties related to unrecognized tax benefits as a component of provision for income taxes.
Foreign Currency Exchange
Foreign Currency Exchange
Adjustments resulting from translating financial statements for those entities that do not have U.S. dollars as their functional currency are recorded as part of a separate component of the consolidated statements of comprehensive income. All assets and liabilities denominated in currencies other than U.S. dollars are translated into the U.S. dollar functional currency at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign currency transaction gains and losses are included in the consolidated statements of comprehensive income for the period.
Indemnification
Indemnification
Our contracts generally include provisions for indemnifying customers against liabilities if our solutions infringe a third party’s intellectual property rights, and we may also incur liabilities if we breach the security and/or confidentiality obligations in our contracts. To date, we have not incurred any material costs, and we have not accrued any liabilities in the accompanying consolidated financial statements as a result of these obligations.
Loss Contingencies
Loss Contingencies
Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
New Accounting Pronouncements Adopted in Fiscal 2022
New Accounting Pronouncements Adopted in Fiscal 2022
Income Taxes
In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” which simplifies accounting guidance for certain tax matters. We adopted this standard effective February 1, 2021. The adoption of this new standard did not have a material impact on our consolidated financial statements.
Fair Value Measurements
Financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:
Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability.
Net Income per Share Attributable to Common Stockholders
Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period.
Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method.
The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares.
v3.22.1
Summary of Business and Significant Accounting Policies (Tables)
12 Months Ended
Jan. 31, 2022
Accounting Policies [Abstract]  
Schedule of Certain Risks and Concentrations of Credit Risk
The following customers individually exceeded 10% of total accounts receivable as of the dates shown:
January 31,
20222021
Customer 110%12%
Customer 210%*
 * Does not exceed 10%.
Schedule of Estimated Useful Lives of Property and Equipment The estimated useful lives by asset classification are as follows:
Building30 years
Land and building improvements10 years(land improvements) and estimated useful life of building (building improvements)
Equipment and computers3 years
Furniture and fixtures5 years
Leasehold improvementsShorter of remaining life of the lease term or estimated useful life
Property and equipment, net consists of the following as of the dates shown (in thousands):
January 31,
20222021
Land$3,040 $3,040 
Building20,984 20,984 
Land improvements and building improvements22,392 22,392 
Equipment and computers3,581 8,847 
Furniture and fixtures15,040 13,452 
Leasehold improvements19,002 13,945 
Construction in progress730 606 
84,769 83,266 
Less accumulated depreciation(30,274)(29,616)
Total property and equipment, net$54,495 $53,650 
v3.22.1
Acquisitions (Tables)
12 Months Ended
Jan. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Estimated Fair Values of Assets and Liabilities Assumed
The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands):
Useful lifeFair value
Net assets acquired$4,766 
Identifiable intangible assets:
Customer relationships10 years70,100 
Existing technology6 years19,200 
Trade name and trademarks5 years13,200 
Other intangibles1to7 years6,000 
Total purchased intangible assets108,500 
Goodwill314,642 
Total purchase consideration$427,908 
The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands):
Useful lifeFair value
Net assets acquired$1,221 
Identifiable intangible assets:
Customer relationships10 years$7,700
Existing technology6 years3,300 
Trade name and trademarks5 years700 
Total purchased intangible assets11,700 
Goodwill28,083 
Total purchase consideration$41,004 
Schedule of Pro Forma Information from Business Acquisition Accordingly, these unaudited pro forma results are presented for information purpose only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations (in thousands):
Fiscal Year Ended January 31,
2020
Pro forma revenues$1,153,497 
Pro forma net income$278,215 
Pro forma net income per share:
     Basic$1.88 
     Diluted$1.76 
v3.22.1
Short-Term Investments (Tables)
12 Months Ended
Jan. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Short-Term Investments
At January 31, 2022, short-term investments consisted of the following (in thousands):
Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Estimated
fair
value
Available-for-sale securities:
Certificates of deposits$13,500 $— $(15)$13,485 
Asset-backed securities191,676 45 (1,432)190,289 
Commercial paper29,432 — (2)29,430 
Corporate notes and bonds669,489 276 (5,856)663,909 
Foreign government bonds24,577 13 (179)24,411 
U.S. agency obligations27,978 12 (254)27,736 
U.S. treasury securities290,513 46 (1,755)288,804 
Total available-for-sale securities$1,247,165 $392 $(9,493)$1,238,064 
At January 31, 2021, short-term investments consisted of the following (in thousands):
Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Estimated
fair
value
Available-for-sale securities:
Certificates of deposits$17,350 $15 $(1)$17,364 
Asset-backed securities125,833 745 (2)126,576 
Commercial paper57,390 (2)57,396 
Corporate notes and bonds428,710 2,360 (23)431,047 
Foreign government bonds31,855 45 (2)31,898 
U.S. agency obligations52,756 119 — 52,875 
U.S. treasury securities215,379 587 — 215,966 
Total available-for-sale securities$929,273 $3,879 $(30)$933,122 
Summary of Estimated Fair Value of Short-Term Investments, Designated as Available-for-Sale and Classified by Contractual Maturity
The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands):
January 31,
20222021
Due in one year or less$457,948 $428,155 
Due in greater than one year780,116 504,967 
Total short-term investments$1,238,064 $933,122 
Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category
The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2022 (in thousands):
Held for less than 12 months
Fair
value
Gross
unrealized
losses
Certificates of deposits$5,985 $(15)
Asset-backed securities177,056 (1,432)
Commercial paper17,190 (2)
Corporate notes and bonds571,099 (5,856)
Foreign government bonds19,594 (179)
U.S. agency obligations24,725 (254)
U.S. treasury securities247,509 (1,756)
The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2021 (in thousands):
Held for less than 12 months
Fair
value
Gross
unrealized
losses
Certificates of deposits$3,749 $(2)
Asset-backed securities3,318 (1)
Commercial paper17,626 (2)
Corporate notes and bonds29,558 (23)
Foreign government bonds2,679 (2)
v3.22.1
Property and Equipment, Net (Tables)
12 Months Ended
Jan. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net The estimated useful lives by asset classification are as follows:
Building30 years
Land and building improvements10 years(land improvements) and estimated useful life of building (building improvements)
Equipment and computers3 years
Furniture and fixtures5 years
Leasehold improvementsShorter of remaining life of the lease term or estimated useful life
Property and equipment, net consists of the following as of the dates shown (in thousands):
January 31,
20222021
Land$3,040 $3,040 
Building20,984 20,984 
Land improvements and building improvements22,392 22,392 
Equipment and computers3,581 8,847 
Furniture and fixtures15,040 13,452 
Leasehold improvements19,002 13,945 
Construction in progress730 606 
84,769 83,266 
Less accumulated depreciation(30,274)(29,616)
Total property and equipment, net$54,495 $53,650 
v3.22.1
Goodwill and Intangible Assets (Tables)
12 Months Ended
Jan. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Goodwill The following schedule presents the details of goodwill as of January 31, 2022 (dollar amounts in thousands):
Balance as of January 31, 2020$438,529 
Purchase price goodwill reduction from Crossix tax adjustments(2,500)
Balance as of January 31, 2021436,029 
Goodwill from business acquisitions$3,848 
Balance as of January 31, 2022$439,877 
Details of Intangible Assets
The following schedule presents the details of intangible assets as of January 31, 2022 (dollar amounts in thousands):
January 31, 2022
Gross
carrying
amount
Accumulated
amortization
Net
Remaining
useful life
(in years)
Existing technology$28,580 $(12,187)$16,393 3.9
Customer relationships113,157 (38,829)74,328 7.0
Trade name and trademarks13,900 (6,645)7,255 2.8
Other intangibles21,405 (17,441)3,964 3.8
Total intangible assets$177,042 $(75,102)$101,940 
The following schedule presents the details of intangible assets as of January 31, 2021 (dollar amounts in thousands):
January 31, 2021
Gross
carrying
amount
Accumulated
amortization
NetRemaining
useful life
(in years)
Existing technology$26,180 $(8,367)$17,813 4.8
Customer relationships110,643 (27,741)82,902 8.0
Trade name and trademarks13,900 (4,005)9,895 3.8
Other intangibles20,453 (16,468)3,985 5.1
Total intangible assets$171,176 $(56,581)$114,595 
Estimated Amortization Expense
As of January 31, 2022, the estimated amortization expense for intangible assets, for the next five years and thereafter is as follows (in thousands):
Fiscal 2023$19,463 
Fiscal 202419,459 
Fiscal 202518,557 
Fiscal 202614,147 
Fiscal 20278,922 
Thereafter21,392 
Total$101,940 
v3.22.1
Accrued Expenses (Tables)
12 Months Ended
Jan. 31, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses consisted of the following as of the dates shown (in thousands):
January 31,
20222021
Accrued commissions$8,556 $7,498 
Accrued bonus4,677 4,134 
Accrued vacation5,546 4,716 
Payroll tax payable9,487 10,250 
Accrued other compensation and benefits5,568 3,812 
Total accrued compensation and benefits$33,834 $30,410 
Accrued fees payable to salesforce.com$6,521 $6,381 
Taxes payable9,743 13,598 
Accrued third-party professional services subcontractors' fees1,961 1,515 
Other accrued expenses17,884 9,488 
Total accrued expenses and other current liabilities$36,109 $30,982 
v3.22.1
Fair Value Measurements (Tables)
12 Months Ended
Jan. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2022 (in thousands):
Level 1
Level 2
Total
Assets
Cash equivalents:
Money market funds$428,411 $— $428,411 
Corporate notes and bonds— 5,853 5,853 
Asset-backed securities— 2,568 2,568 
Short-term investments:
Certificates of deposits— 13,485 13,485 
Asset-backed securities— 190,289 190,289 
Commercial paper— 29,430 29,430 
Corporate notes and bonds— 663,909 663,909 
Foreign government bonds— 24,411 24,411 
U.S. agency obligations— 27,736 27,736 
U.S. Treasury securities— 288,804 288,804 
Foreign currency derivative contracts— 1,222 1,222 
Total financial assets$428,411 $1,247,707 $1,676,118 
The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2021 (in thousands):
Level 1
Level 2
Total
Assets
Cash equivalents:
Money market funds$259,937 $— $259,937 
U.S. Treasury securities— 15,520 15,520 
Short-term investments:
Certificates of deposits— 17,364 17,364 
Asset-backed securities— 126,576 126,576 
Commercial paper— 57,396 57,396 
Corporate notes and bonds— 431,047 431,047 
Foreign government bonds— 31,898 31,898 
U.S. agency obligations— 52,875 52,875 
U.S. Treasury securities— 215,966 215,966 
Foreign currency derivative contracts— 440 440 
Total financial assets$259,937 $949,082 $1,209,019 
Liabilities
Foreign currency derivative contracts$— $72 $72 
Total financial liabilities$— $72 $72 
Summary Fair Value of Outstanding Derivative Instruments
The fair value of our outstanding derivative instruments is summarized below (in thousands): 
January 31,
20222021
Notional amount of foreign currency derivative contracts$87,097 $52,516 
Fair value of foreign currency derivative contracts85,876 52,148 
Summary of Outstanding Balance Sheet Hedges
Derivatives not designated as hedging instruments are presented as components of the following balance sheet items for the periods shown as follows (in thousands): 
January 31,
Balance sheet presentation20222021
Foreign currency derivative contracts - assetsPrepaid expenses and other current assets$1,222 $440 
Foreign currency derivative contracts - liabilitiesAccrued expenses— 72 
v3.22.1
Income Taxes (Tables)
12 Months Ended
Jan. 31, 2022
Income Tax Disclosure [Abstract]  
Components of Income before Income Taxes
The components of income before income taxes by U.S. and foreign jurisdictions were as follows for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
United States$487,962 $378,042 $305,339 
Foreign24,349 15,951 8,358 
Total$512,311 $393,993 $313,697 
Components of Provision for Income Taxes
Provision for income taxes consisted of the following for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
Current provision:
Federal$53,426 $7,108 $11,143 
State12,580 4,763 4,695 
Foreign7,837 2,825 3,404 
Total current provision73,843 14,696 19,242 
Deferred provision:
Federal1,870 (816)(1,063)
State945 681 (517)
Foreign8,264 (566)(5,083)
Total deferred provision11,079 (701)(6,663)
Provision for income taxes$84,921 $13,995 $12,579 
Reconciliation of Statutory Federal Income Tax to Effective Tax
Provision for income taxes differed from the amount computed by applying the federal statutory income tax rate of 21% for each of the fiscal years ended January 31, 2022, 2021, and 2020 to income before income taxes as a result of the following for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
Federal tax statutory tax rate$107,585 $82,739 $65,876 
State taxes11,035 4,401 3,035 
Tax credits(25,968)(24,617)(23,468)
Stock-based compensation(29,715)(54,488)(34,569)
Valuation allowance19,402 10,269 7,408 
Foreign derived intangible income deduction (FDII)(3,406)(5,134)(4,836)
Other(1)
5,988 825 (867)
Provision for income taxes$84,921 $13,995 $12,579 
(1) Prior period balances were adjusted to conform with current period presentation.
Components of Deferred Tax Assets and Liabilities
The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and liabilities related to the following (in thousands):
January 31,
20222021
Deferred tax assets:
Accruals and reserves$7,068 $13,494 
Capitalized expenditures10,477 — 
Stock-based compensation16,615 11,486 
Net operating loss carryforward21,850 29,318 
Tax credit carryforward34,725 29,624 
Lease liabilities13,813 15,932 
Other(1)
2,955 977 
Gross deferred tax assets107,503 100,831 
Valuation allowance(48,484)(31,318)
Total deferred tax assets59,019 69,513 
Deferred tax liabilities:
Intangible assets(31,200)(30,253)
Lease right-of-use assets(12,497)(14,438)
Deferred costs(1)
(10,552)(11,481)
Other(1)
(1,889)(1,076)
Total deferred tax liabilities(56,138)(57,248)
Net deferred tax assets$2,881 $12,265 
(1) Prior period balances were adjusted to conform with current period presentation.
Summary of Changes in Total Gross Amount of Unrecognized Tax Benefits The aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows for the periods shown (in thousands):
Fiscal year ended January 31,
202220212020
Beginning balance$18,628 $14,515 $12,597 
Increases related to tax positions taken during the prior period3,218 96 796 
Increases related to tax positions taken during the current period4,122 4,126 3,420 
Decreases related to tax positions taken during the prior period— (51)(128)
Audit settlements(195)— — 
Lapse of statute of limitations(532)(58)(2,170)
Ending balance$25,241 $18,628 $14,515 
v3.22.1
Leases (Tables)
12 Months Ended
Jan. 31, 2022
Leases [Abstract]  
Supplemental Cash Flow Information Related to Leases
Supplemental cash flow information related to leases was as follows (in thousands):
Fiscal year ended January 31,
20222021
Cash paid for amounts included in the measurement of lease liabilities$13,800 $11,401 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases3,848 12,214 
Supplemental Balance Sheet Information Related to Leases
Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate):
January 31,
20222021
Lease right-of-use assets$49,640 $56,917 
Lease liabilities$10,981 $11,347 
Lease liabilities, noncurrent43,607 51,393 
Total operating lease liabilities$54,588 $62,740 
Weighted Average Remaining Lease Term6.0 years6.7 years
Weighted Average Discount Rate3.7 %3.8 %
Maturity of Operating Lease Liabilities
As of January 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands):
Fiscal 2023$12,143 
Fiscal 202411,942 
Fiscal 20258,951 
Fiscal 20267,251 
Fiscal 20276,316 
Thereafter14,674 
Total operating lease payments61,277 
Less imputed interest6,689 
Total operating lease liabilities$54,588 
v3.22.1
Stockholders' Equity (Tables)
12 Months Ended
Jan. 31, 2022
Share-based Payment Arrangement [Abstract]  
Summary of Stock Option Activity A summary of stock option activity for the fiscal year ended January 31, 2022 is as follows: 
Number
of shares
Weighted
average
exercise
price
Weighted
average
remaining
contractual
term (in years)
Aggregate
intrinsic
value
(in millions)
Options outstanding at January 31, 202112,761,289 $57.48 5.0$2,794 
Options granted1,155,396 277.06 
Options exercised(1,476,898)34.90 
Options forfeited/cancelled(349,265)172.64 
Options outstanding at January 31, 202212,090,522 $77.89 4.6$1,964 
Options vested and exercisable at January 31, 20227,203,834 $32.35 2.8$1,472 
Options vested and exercisable at January 31, 2022 and expected to vest thereafter12,090,522 $77.89 4.6$1,964 
Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted
The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented:
Fiscal year ended January 31,
202220212020
Volatility37%-39%39%-42%39%-41%
Expected term (in years)6.256.25-7.255.64-6.61
Risk-free interest rate0.70%-1.60%0.33%-1.43%1.39%-2.52%
Dividend yield—%—%—%
Summary of Restricted Stock Unit (RSU) Activity A summary of RSU activity for the fiscal year ended January 31, 2022 is as follows:
Unreleased restricted
stock units
Weighted 
average grant
date fair value
Balance at January 31, 20211,032,215 $121.98 
RSUs granted518,172 277.79 
RSUs vested(854,536)173.01 
RSUs forfeited / cancelled(76,463)175.88 
Balance at January 31, 2022619,388 175.23 
v3.22.1
Other Income (Tables)
12 Months Ended
Jan. 31, 2022
Other Income and Expenses [Abstract]  
Schedule of Other Income
Other income, net, consisted of the following (in thousands):
Fiscal year ended January 31,
202220212020
Foreign currency (loss) gain$(714)$2,275 $(708)
(Amortization) accretion on investments(7,201)(3,082)3,001 
Interest income, net14,730 15,859 25,185 
Miscellaneous income— 1,147 — 
Other income, net$6,815 $16,199 $27,478 
v3.22.1
Net Income per Share (Tables)
12 Months Ended
Jan. 31, 2022
Earnings Per Share [Abstract]  
Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock
The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data):
Fiscal year ended January 31,
202220212020
Class AClass BClass AClass BClass AClass B
Basic
Numerator
Net income, basic$386,180 $41,210 $341,866 $38,132 $266,104 $35,014 
Denominator
Weighted average shares used in computing net income per share, basic138,474 14,777 135,547 15,119 130,610 17,186 
Net income per share, basic$2.79 $2.79 $2.52 $2.52 $2.04 $2.04 
Diluted
Numerator
Net income, basic$386,180 $41,210 $341,866 $38,132 $266,104 $35,014 
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic41,210 — 38,132 — 35,014 — 
Reallocation of net income to Class B common stock— 21,480 — 21,409 — 17,652 
Net income, diluted$427,390 $62,690 $379,998 $59,541 $301,118 $52,666 
Denominator
Number of shares used for basic net income per share computation138,474 14,777 135,547 15,119 130,610 17,186 
Conversion of Class B to Class A common stock14,777 — 15,119 — 17,186 — 
Effect of potentially dilutive common shares9,026 9,026 10,066 10,066 10,500 10,500 
Weighted average shares used in computing net income per share, diluted162,277 23,803 160,732 25,185 158,296 27,686 
Net income per share, diluted$2.63 $2.63 $2.36 $2.36 $1.90 $1.90 
Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive
Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows:
Fiscal year ended January 31,
202220212020
Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive958,476 1,045,222 1,461,255 
v3.22.1
Revenues by Product (Tables)
12 Months Ended
Jan. 31, 2022
Revenue from Contract with Customer [Abstract]  
Summary of Total Revenues
Total revenues consist of the following (in thousands):
Fiscal year ended January 31,
202220212020
Subscription services
Commercial Solutions$876,458 $744,856 $593,562 
R&D Solutions607,518 434,630 302,732 
Total subscription services1,483,976 1,179,486 896,294 
Professional services
Commercial Solutions165,086 142,003 103,825 
R&D Solutions201,715 143,580 103,962 
Total professional services366,801 285,583 207,787 
Total revenues$1,850,777 $1,465,069 $1,104,081 
v3.22.1
Information about Geographic Areas (Tables)
12 Months Ended
Jan. 31, 2022
Segment Reporting [Abstract]  
Revenues by Geographic Area
Total revenues by geographic area were as follows for the periods shown below (in thousands):
Fiscal year ended January 31,
202220212020
North America$1,063,770 $838,192 $607,704 
Europe509,127 400,790 310,215 
Asia Pacific225,968 183,848 151,052 
Middle East, Africa, and Latin America51,912 42,239 35,110 
Total revenues$1,850,777 $1,465,069 $1,104,081 
Long-Lived Assets by Geographic Area
Long-lived assets by geographic area are as follows as of the periods shown below (in thousands):
January 31,
20222021
North America$45,625 $46,285 
Europe6,135 5,525 
Asia Pacific1,335 1,359 
Middle East, Africa, and Latin America1,400 481 
Total long-lived assets$54,495 $53,650 
v3.22.1
Summary of Business and Significant Accounting Policies - Additional Information (Details)
12 Months Ended
Jan. 31, 2022
USD ($)
segment
Concentration Risk [Line Items]  
Number of operating segments | segment 1
Number of reportable segments | segment 1
Highly liquid investments maturity 3 months
Impairment of goodwill | $ $ 0
Impairment recognized for long-lived assets | $ $ 0
Software Development  
Concentration Risk [Line Items]  
Finite-lived intangible asset, useful life 3 years
Minimum  
Concentration Risk [Line Items]  
Amortization period of deferred costs 1 year
Customer payment period 30 days
Minimum | 2007 Stock Plan | Restricted Stock Units (RSUs)  
Concentration Risk [Line Items]  
Share-based compensation cost recognition vesting service period 1 year
Minimum | 2007 Stock Plan | Stock Options  
Concentration Risk [Line Items]  
Share-based compensation cost recognition vesting service period 4 years
Maximum  
Concentration Risk [Line Items]  
Amortization period of deferred costs 3 years
Customer payment period 60 days
Maximum | 2007 Stock Plan | Restricted Stock Units (RSUs)  
Concentration Risk [Line Items]  
Share-based compensation cost recognition vesting service period 5 years
Maximum | 2007 Stock Plan | Stock Options  
Concentration Risk [Line Items]  
Share-based compensation cost recognition vesting service period 9 years
v3.22.1
Summary of Business and Significant Accounting Policies - Concentrations of Credit Risk (Details) - Accounts Receivable - Customer Concentration Risk
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Customer One    
Concentration Risk [Line Items]    
Concentration risk, percentage 10.00% 12.00%
Customer Two    
Concentration Risk [Line Items]    
Concentration risk, percentage 10.00%  
v3.22.1
Summary of Business and Significant Accounting Policies - Estimated Useful Lives (Details)
12 Months Ended
Jan. 31, 2022
Building  
Property, Plant and Equipment [Line Items]  
Property and equipment, estimated useful life 30 years
Land improvements and building improvements  
Property, Plant and Equipment [Line Items]  
Property and equipment, estimated useful life 10 years
Equipment and computers  
Property, Plant and Equipment [Line Items]  
Property and equipment, estimated useful life 3 years
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Property and equipment, estimated useful life 5 years
Leasehold improvements  
Property, Plant and Equipment [Line Items]  
Property and equipment, estimated useful life Shorter of remaining life of the lease term or estimated useful life
v3.22.1
Acquisitions - Additional Information (Details) - USD ($)
$ in Millions
Nov. 07, 2019
Nov. 01, 2019
Crossix Solutions    
Business Acquisition [Line Items]    
Percentage of voting interests acquired   100.00%
Consideration transferred   $ 428
Equity retention awards   $ 120
Physicians World    
Business Acquisition [Line Items]    
Consideration transferred $ 41  
Equity retention awards $ 15  
v3.22.1
Acquisitions - Schedule of Assets and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Nov. 07, 2019
Nov. 01, 2019
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Business Acquisition [Line Items]          
Goodwill     $ 439,877 $ 436,029 $ 438,529
Crossix Solutions          
Business Acquisition [Line Items]          
Net assets acquired   $ 4,766      
Total purchased intangible assets   108,500      
Goodwill   314,642      
Total purchase consideration   427,908      
Crossix Solutions | Customer relationships          
Business Acquisition [Line Items]          
Total purchased intangible assets   $ 70,100      
Useful life of intangible assets   10 years      
Crossix Solutions | Developed Technology Rights          
Business Acquisition [Line Items]          
Total purchased intangible assets   $ 19,200      
Useful life of intangible assets   6 years      
Crossix Solutions | Trade name and trademarks          
Business Acquisition [Line Items]          
Total purchased intangible assets   $ 13,200      
Useful life of intangible assets   5 years      
Crossix Solutions | Other intangibles          
Business Acquisition [Line Items]          
Total purchased intangible assets   $ 6,000      
Crossix Solutions | Other intangibles | Minimum          
Business Acquisition [Line Items]          
Useful life of intangible assets   1 year      
Crossix Solutions | Other intangibles | Maximum          
Business Acquisition [Line Items]          
Useful life of intangible assets   7 years      
Physicians World          
Business Acquisition [Line Items]          
Net assets acquired $ 1,221        
Total purchased intangible assets 11,700        
Goodwill 28,083        
Total purchase consideration 41,004        
Physicians World | Customer relationships          
Business Acquisition [Line Items]          
Total purchased intangible assets $ 7,700        
Useful life of intangible assets 10 years        
Physicians World | Developed Technology Rights          
Business Acquisition [Line Items]          
Total purchased intangible assets $ 3,300        
Useful life of intangible assets 6 years        
Physicians World | Trade name and trademarks          
Business Acquisition [Line Items]          
Total purchased intangible assets $ 700        
Useful life of intangible assets 5 years        
v3.22.1
Acquisitions - Schedule of Pro Forma Information (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Jan. 31, 2021
USD ($)
$ / shares
Business Combination and Asset Acquisition [Abstract]  
Pro forma revenues | $ $ 1,153,497
Pro forma net income | $ $ 278,215
Pro forma net income per share:  
Basic (in dollars per share) | $ / shares $ 1.88
Diluted (in dollars per share) | $ / shares $ 1.76
v3.22.1
Short-Term Investments - Schedule of Short-Term Investments (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost $ 1,247,165 $ 929,273
Gross unrealized gains 392 3,879
Gross unrealized losses (9,493) (30)
Estimated fair value 1,238,064 933,122
Certificates of deposits    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 13,500 17,350
Gross unrealized gains 0 15
Gross unrealized losses (15) (1)
Estimated fair value 13,485 17,364
Asset-backed securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 191,676 125,833
Gross unrealized gains 45 745
Gross unrealized losses (1,432) (2)
Estimated fair value 190,289 126,576
Commercial paper    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 29,432 57,390
Gross unrealized gains 0 8
Gross unrealized losses (2) (2)
Estimated fair value 29,430 57,396
Corporate notes and bonds    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 669,489 428,710
Gross unrealized gains 276 2,360
Gross unrealized losses (5,856) (23)
Estimated fair value 663,909 431,047
Foreign government bonds    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 24,577 31,855
Gross unrealized gains 13 45
Gross unrealized losses (179) (2)
Estimated fair value 24,411 31,898
U.S. agency obligations    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 27,978 52,756
Gross unrealized gains 12 119
Gross unrealized losses (254) 0
Estimated fair value 27,736 52,875
U.S. treasury securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 290,513 215,379
Gross unrealized gains 46 587
Gross unrealized losses (1,755) 0
Estimated fair value $ 288,804 $ 215,966
v3.22.1
Short-Term Investments - Summary of Estimated Fair Value of Short-Term Investments, Designated as Available-for-Sale and Classified by Contractual Maturity (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Due in one year or less $ 457,948 $ 428,155
Due in greater than one year 780,116 504,967
Total short-term investments $ 1,238,064 $ 933,122
v3.22.1
Short-Term Investments - Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Certificates of deposits    
Schedule of Available-for-sale Securities [Line Items]    
Fair value $ 5,985 $ 3,749
Gross unrealized losses (15) (2)
Asset-backed securities    
Schedule of Available-for-sale Securities [Line Items]    
Fair value 177,056 3,318
Gross unrealized losses (1,432) (1)
Commercial paper    
Schedule of Available-for-sale Securities [Line Items]    
Fair value 17,190 17,626
Gross unrealized losses (2) (2)
Corporate notes and bonds    
Schedule of Available-for-sale Securities [Line Items]    
Fair value 571,099 29,558
Gross unrealized losses (5,856) (23)
Foreign government bonds    
Schedule of Available-for-sale Securities [Line Items]    
Fair value 19,594 2,679
Gross unrealized losses (179) $ (2)
U.S. agency obligations    
Schedule of Available-for-sale Securities [Line Items]    
Fair value 24,725  
Gross unrealized losses (254)  
U.S. treasury securities    
Schedule of Available-for-sale Securities [Line Items]    
Fair value 247,509  
Gross unrealized losses $ (1,756)  
v3.22.1
Deferred Costs (Details) - USD ($)
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Deferred Costs [Abstract]      
Deferred costs $ 33,106,000 $ 42,072,000  
Amortization of deferred costs 26,000,000 21,000,000 $ 21,000,000
Impairment losses recorded in relation to the costs capitalized $ 0 $ 0 $ 0
v3.22.1
Property and Equipment, Net - Components of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 84,769 $ 83,266
Less accumulated depreciation (30,274) (29,616)
Total property and equipment, net 54,495 53,650
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,040 3,040
Building    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 20,984 20,984
Land improvements and building improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 22,392 22,392
Equipment and computers    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,581 8,847
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 15,040 13,452
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 19,002 13,945
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 730 $ 606
v3.22.1
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Property, Plant and Equipment [Abstract]      
Depreciation $ 7 $ 9 $ 9
v3.22.1
Goodwill and Intangible Assets - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Intangible Assets, Net (Excluding Goodwill) [Abstract]      
Goodwill $ 439,877 $ 436,029 $ 438,529
Amortization expense $ 19,000 $ 20,000 $ 10,000
v3.22.1
Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Goodwill [Roll Forward]    
Goodwill, beginning balance $ 436,029 $ 438,529
Purchase price goodwill reduction from Crossix tax adjustments   (2,500)
Goodwill from business acquisitions 3,848  
Goodwill, ending balance $ 439,877 $ 436,029
v3.22.1
Goodwill and Intangible Assets - Details of Intangible Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 177,042 $ 171,176
Accumulated amortization (75,102) (56,581)
Net 101,940 114,595
Existing technology    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 28,580 26,180
Accumulated amortization (12,187) (8,367)
Net $ 16,393 $ 17,813
Remaining useful life (in years) 3 years 10 months 24 days 4 years 9 months 18 days
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 113,157 $ 110,643
Accumulated amortization (38,829) (27,741)
Net $ 74,328 $ 82,902
Remaining useful life (in years) 7 years 8 years
Trade name and trademarks    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 13,900 $ 13,900
Accumulated amortization (6,645) (4,005)
Net $ 7,255 $ 9,895
Remaining useful life (in years) 2 years 9 months 18 days 3 years 9 months 18 days
Other intangibles    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 21,405 $ 20,453
Accumulated amortization (17,441) (16,468)
Net $ 3,964 $ 3,985
Remaining useful life (in years) 3 years 9 months 18 days 5 years 1 month 6 days
v3.22.1
Goodwill and Intangible Assets - Estimated Amortization Expense (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]    
Fiscal 2023 $ 19,463  
Fiscal 2024 19,459  
Fiscal 2025 18,557  
Fiscal 2026 14,147  
Fiscal 2027 8,922  
Thereafter 21,392  
Net $ 101,940 $ 114,595
v3.22.1
Accrued Expenses (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Payables and Accruals [Abstract]    
Accrued commissions $ 8,556 $ 7,498
Accrued bonus 4,677 4,134
Accrued vacation 5,546 4,716
Payroll tax payable 9,487 10,250
Accrued other compensation and benefits 5,568 3,812
Total accrued compensation and benefits 33,834 30,410
Accrued fees payable to salesforce.com 6,521 6,381
Taxes payable 9,743 13,598
Accrued third-party professional services subcontractors' fees 1,961 1,515
Other accrued expenses 17,884 9,488
Total accrued expenses and other current liabilities $ 36,109 $ 30,982
v3.22.1
Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Assets    
Short-term investments $ 1,238,064 $ 933,122
U.S. treasury securities    
Assets    
Short-term investments 288,804 215,966
Certificates of deposits    
Assets    
Short-term investments 13,485 17,364
Asset-backed securities    
Assets    
Short-term investments 190,289 126,576
Commercial paper    
Assets    
Short-term investments 29,430 57,396
Corporate notes and bonds    
Assets    
Short-term investments 663,909 431,047
Foreign government bonds    
Assets    
Short-term investments 24,411 31,898
U.S. agency obligations    
Assets    
Short-term investments 27,736 52,875
Fair value, measurements recurring    
Assets    
Total financial assets 1,676,118 1,209,019
Liabilities    
Total financial liabilities   72
Fair value, measurements recurring | Money market funds    
Assets    
Cash equivalents: 428,411 259,937
Fair value, measurements recurring | U.S. treasury securities    
Assets    
Cash equivalents:   15,520
Short-term investments 288,804 215,966
Fair value, measurements recurring | Certificates of deposits    
Assets    
Short-term investments 13,485 17,364
Fair value, measurements recurring | Asset-backed securities    
Assets    
Cash equivalents: 2,568  
Short-term investments 190,289 126,576
Fair value, measurements recurring | Commercial paper    
Assets    
Short-term investments 29,430 57,396
Fair value, measurements recurring | Corporate notes and bonds    
Assets    
Cash equivalents: 5,853  
Short-term investments 663,909 431,047
Fair value, measurements recurring | Foreign government bonds    
Assets    
Short-term investments 24,411 31,898
Fair value, measurements recurring | U.S. agency obligations    
Assets    
Short-term investments 27,736 52,875
Fair value, measurements recurring | Foreign currency derivative contracts    
Assets    
Short-term investments 1,222 440
Fair value, measurements recurring | Foreign currency derivative contracts    
Liabilities    
Foreign currency derivative contracts   72
Fair value, measurements recurring | Level 1    
Assets    
Total financial assets 428,411 259,937
Liabilities    
Total financial liabilities   0
Fair value, measurements recurring | Level 1 | Money market funds    
Assets    
Cash equivalents: 428,411 259,937
Fair value, measurements recurring | Level 1 | U.S. treasury securities    
Assets    
Cash equivalents:   0
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | Certificates of deposits    
Assets    
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | Asset-backed securities    
Assets    
Cash equivalents: 0  
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | Commercial paper    
Assets    
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | Corporate notes and bonds    
Assets    
Cash equivalents: 0  
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | Foreign government bonds    
Assets    
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | U.S. agency obligations    
Assets    
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | Foreign currency derivative contracts    
Assets    
Short-term investments 0 0
Fair value, measurements recurring | Level 1 | Foreign currency derivative contracts    
Liabilities    
Foreign currency derivative contracts   0
Fair value, measurements recurring | Level 2    
Assets    
Total financial assets 1,247,707 949,082
Liabilities    
Total financial liabilities   72
Fair value, measurements recurring | Level 2 | Money market funds    
Assets    
Cash equivalents: 0 0
Fair value, measurements recurring | Level 2 | U.S. treasury securities    
Assets    
Cash equivalents:   15,520
Short-term investments 288,804 215,966
Fair value, measurements recurring | Level 2 | Certificates of deposits    
Assets    
Short-term investments 13,485 17,364
Fair value, measurements recurring | Level 2 | Asset-backed securities    
Assets    
Cash equivalents: 2,568  
Short-term investments 190,289 126,576
Fair value, measurements recurring | Level 2 | Commercial paper    
Assets    
Short-term investments 29,430 57,396
Fair value, measurements recurring | Level 2 | Corporate notes and bonds    
Assets    
Cash equivalents: 5,853  
Short-term investments 663,909 431,047
Fair value, measurements recurring | Level 2 | Foreign government bonds    
Assets    
Short-term investments 24,411 31,898
Fair value, measurements recurring | Level 2 | U.S. agency obligations    
Assets    
Short-term investments 27,736 52,875
Fair value, measurements recurring | Level 2 | Foreign currency derivative contracts    
Assets    
Short-term investments $ 1,222 440
Fair value, measurements recurring | Level 2 | Foreign currency derivative contracts    
Liabilities    
Foreign currency derivative contracts   $ 72
v3.22.1
Fair Value Measurements - Summary Fair Value of Outstanding Derivative Instruments (Details) - Foreign currency derivative contracts - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Derivatives, Fair Value [Line Items]    
Notional amount of foreign currency derivative contracts $ 87,097 $ 52,516
Fair value of foreign currency derivative contracts $ 85,876 $ 52,148
v3.22.1
Fair Value Measurements - Summary of Outstanding Balance Sheet Hedges (Details) - Foreign currency derivative contracts - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Foreign currency derivative contracts - assets $ 1,222 $ 440
Accrued expenses    
Derivatives, Fair Value [Line Items]    
Foreign currency derivative contracts - liabilities $ 0 $ 72
v3.22.1
Income Taxes - Components of Income before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Income Tax Disclosure [Abstract]      
United States $ 487,962 $ 378,042 $ 305,339
Foreign 24,349 15,951 8,358
Income before income taxes $ 512,311 $ 393,993 $ 313,697
v3.22.1
Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Current provision:      
Federal $ 53,426 $ 7,108 $ 11,143
State 12,580 4,763 4,695
Foreign 7,837 2,825 3,404
Total current provision 73,843 14,696 19,242
Deferred provision:      
Federal 1,870 (816) (1,063)
State 945 681 (517)
Foreign 8,264 (566) (5,083)
Total deferred provision 11,079 (701) (6,663)
Provision for income taxes $ 84,921 $ 13,995 $ 12,579
v3.22.1
Income Taxes - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Income Tax Contingency [Line Items]        
Federal statutory income tax rate 21.00% 21.00% 21.00%  
Federal net operating loss carryforwards $ 48,000      
State net operating loss carryforwards 69,000      
Foreign net operating loss carryforwards 31,000      
Unrecognized tax benefits 25,241 $ 18,628 $ 14,515 $ 12,597
Unrecognized tax benefits that would impact effective tax rate 14,000      
State and Local Jurisdiction | California Franchise Tax Board        
Income Tax Contingency [Line Items]        
Tax credit carryforward $ 54,000      
v3.22.1
Income Taxes - Reconciliation of Statutory Federal Income Tax to Effective Tax (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Income Tax Disclosure [Abstract]      
Federal tax statutory tax rate $ 107,585 $ 82,739 $ 65,876
State taxes 11,035 4,401 3,035
Tax credits (25,968) (24,617) (23,468)
Stock-based compensation (29,715) (54,488) (34,569)
Valuation allowance 19,402 10,269 7,408
Foreign derived intangible income deduction (FDII) (3,406) (5,134) (4,836)
Other 5,988 825 (867)
Provision for income taxes $ 84,921 $ 13,995 $ 12,579
v3.22.1
Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Deferred tax assets:    
Accruals and reserves $ 7,068 $ 13,494
Capitalized expenditures 10,477 0
Stock-based compensation 16,615 11,486
Net operating loss carryforward 21,850 29,318
Tax credit carryforward 34,725 29,624
Lease liabilities 13,813 15,932
Other 2,955 977
Gross deferred tax assets 107,503 100,831
Valuation allowance (48,484) (31,318)
Total deferred tax assets 59,019 69,513
Deferred tax liabilities:    
Intangible assets (31,200) (30,253)
Lease right-of-use assets (12,497) (14,438)
Deferred costs (10,552) (11,481)
Other (1,889) (1,076)
Total deferred tax liabilities (56,138) (57,248)
Net deferred tax assets $ 2,881 $ 12,265
v3.22.1
Income Taxes - Summary of Changes in Total Gross Amount of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance $ 18,628 $ 14,515 $ 12,597
Increases related to tax positions taken during the prior period 3,218 96 796
Increases related to tax positions taken during the current period 4,122 4,126 3,420
Decreases related to tax positions taken during the prior period 0 (51) (128)
Audit settlements (195) 0 0
Lapse of statute of limitations (532) (58) (2,170)
Ending balance $ 25,241 $ 18,628 $ 14,515
v3.22.1
Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Revenue From Contracts With Customers [Line Items]      
Unbilled accounts receivable $ 63,266 $ 47,206  
Subscription services      
Revenue From Contracts With Customers [Line Items]      
Recognition of deferred revenue 605,000 464,000 $ 353,000
Revenue expected to be recognized from remaining performance obligations 1,507,000    
Unbilled accounts receivable 36,000 27,000  
Professional services and other      
Revenue From Contracts With Customers [Line Items]      
Unbilled accounts receivable $ 28,000 $ 20,000  
v3.22.1
Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Performance Obligation Duration (Details) - Subscription services - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01
Jan. 31, 2022
Revenue From Contracts With Customers [Line Items]  
Revenue, remaining performance obligation, percentage 79.00%
Revenue, remaining performance obligation, recognition period 12 months
v3.22.1
Leases - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Leases [Line Items]      
Operating lease expense $ 14 $ 13 $ 8
Maximum      
Leases [Line Items]      
Operating leases, options to extend leases term 9 years    
Finance leases, options to extend leases term 9 years    
v3.22.1
Leases - Supplemental Cash Flow Information Related to Leases (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Leases [Abstract]    
Cash paid for amounts included in the measurement of lease liabilities $ 13,800 $ 11,401
Right-of-use assets obtained in exchange for lease obligations:    
Operating leases $ 3,848 $ 12,214
v3.22.1
Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Leases [Abstract]    
Lease right-of-use assets $ 49,640 $ 56,917
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Lease liabilities Lease liabilities
Lease liabilities $ 10,981 $ 11,347
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Lease liabilities, noncurrent Lease liabilities, noncurrent
Lease liabilities, noncurrent $ 43,607 $ 51,393
Total operating lease liabilities $ 54,588 $ 62,740
Weighted Average Remaining Lease Term 6 years 6 years 8 months 12 days
Weighted Average Discount Rate 3.70% 3.80%
v3.22.1
Leases- Maturities of Lease Liabilities (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]    
Fiscal 2023 $ 12,143  
Fiscal 2024 11,942  
Fiscal 2025 8,951  
Fiscal 2026 7,251  
Fiscal 2027 6,316  
Thereafter 14,674  
Total operating lease payments 61,277  
Less imputed interest 6,689  
Total operating lease liabilities $ 54,588 $ 62,740
v3.22.1
Stockholders' Equity - Additional Information (Details)
12 Months Ended
Jan. 31, 2022
USD ($)
vote
$ / shares
shares
Jan. 31, 2021
$ / shares
shares
Jan. 31, 2020
$ / shares
Jan. 29, 2021
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Dividends payable | $ $ 0      
Options outstanding (in shares) 12,090,522 12,761,289    
Unrecognized compensation cost related to unvested stock options granted | $ $ 229,000,000      
Share price (in usd per share) | $ / shares       $ 236.54
Intrinsic value of options exercised | $ $ 363,000,000      
Class A common stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Common stock, shares issued (in shares) 139,432,822 137,062,817    
Common stock, shares outstanding (in shares) 139,432,822 137,062,817    
Vote per common share | vote 1      
Class B common stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Common stock, shares issued (in shares) 14,763,775 14,993,991    
Common stock, shares outstanding (in shares) 14,763,775 14,993,991    
Vote per common share | vote 10      
2007 Stock Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options outstanding (in shares) 0      
2021 Equity Incentive Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options outstanding (in shares) 0      
2013 Equity Incentive Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options outstanding (in shares) 0      
Number of additional shares authorized (in shares) 13,750,000      
Common stock, shares outstanding, percentage 5.00%      
Weighted-average grant date fair value of options granted (in usd per share) | $ / shares $ 108.42 $ 71.86 $ 60.05  
2013 Equity Incentive Plan | Director        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares issued in period (in shares) 6,082,272      
2013 Equity Incentive Plan | Class A common stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares available for issuance (in shares) 38,720,277      
2013 Employee Stock Purchase Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of additional shares authorized (in shares) 2,200,000      
Common stock, shares outstanding, percentage 1.00%      
Number of shares reserved for future issuance (in shares) 4,000,000      
Number of shares authorized (in shares) 4,897,856      
Percent of fair market value paid for shares 85.00%      
Percentage of payroll deductions for shares acquired 15.00%      
2013 Employee Stock Purchase Plan | Director        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares issued in period (in shares) 0      
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period 1 year      
Weighted average period of unvested stock (in years) 1 year 2 months 12 days      
Unrecognized compensation cost related to unvested RSUs | $ $ 90,000,000      
Total intrinsic value, vested | $ $ 246,000,000      
Restricted Stock Units (RSUs) | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period 4 years      
Restricted Stock Units (RSUs) | 2007 Stock Plan | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation cost recognition vesting service period 1 year      
Restricted Stock Units (RSUs) | 2007 Stock Plan | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation cost recognition vesting service period 5 years      
Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period 4 years      
Weighted average period of unvested stock (in years) 2 years 7 months 6 days      
Stock Options | 2007 Stock Plan | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period 4 years      
Share-based compensation cost recognition vesting service period 4 years      
Stock Options | 2007 Stock Plan | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period 5 years      
Options exercisable period 10 years      
Share-based compensation cost recognition vesting service period 9 years      
Stock Options | 2013 Equity Incentive Plan | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period 5 years      
Stock Options | 2013 Equity Incentive Plan | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period 9 years      
Options exercisable period 10 years      
v3.22.1
Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Number of shares    
Options outstanding, beginning balance (in shares) 12,761,289  
Options granted (in shares) 1,155,396  
Options exercised (in shares) (1,476,898)  
Options forfeited/cancelled (in shares) (349,265)  
Options outstanding, ending balance (in shares) 12,090,522 12,761,289
Options vested and exercisable (in shares) 7,203,834  
Options vested and exercisable and expected to vest thereafter (in shares) 12,090,522  
Weighted average exercise price    
Options outstanding, beginning balance (in usd per share) $ 57.48  
Options granted (in usd per share) 277.06  
Options exercised (in usd per share) 34.90  
Options forfeited/cancelled (in usd per share) 172.64  
Options outstanding, ending balance (in usd per share) 77.89 $ 57.48
Options vested and exercisable (in usd per share) 32.35  
Options vested and exercisable and expected to vest thereafter (in usd per share) $ 77.89  
Weighted average remaining contractual term (in years), options outstanding 4 years 7 months 6 days 5 years
Weighted average remaining contractual term (in years), options vested and exercisable 2 years 9 months 18 days  
Weighted average remaining contractual term (in years), options vested and exercisable and expected to vest thereafter 4 years 7 months 6 days  
Aggregate intrinsic value (in millions)    
Options outstanding $ 1,964 $ 2,794
Options vested and exercisable 1,472  
Options vested and exercisable and expected to vest thereafter $ 1,964  
v3.22.1
Stockholders' Equity - Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted (Details) - Stock Options
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate, minimum 0.70% 0.33% 1.39%
Risk-free interest rate, maximum 1.60% 1.43% 2.52%
Dividend yield 0.00% 0.00% 0.00%
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Volatility 37.00% 39.00% 39.00%
Expected term (in years) 6 years 3 months 6 years 3 months 5 years 7 months 20 days
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Volatility 39.00% 42.00% 41.00%
Expected term (in years)   7 years 3 months 6 years 7 months 9 days
v3.22.1
Stockholders' Equity - Summary of Restricted Stock Unit (RSU) Activity (Details) - Restricted Stock Units (RSUs)
12 Months Ended
Jan. 31, 2022
$ / shares
shares
Unreleased restricted stock units  
Beginning balance (in shares) | shares 1,032,215
RSUs granted (in shares) | shares 518,172
RSUs vested (in shares) | shares (854,536)
RSUs forfeited/cancelled (in shares) | shares (76,463)
Ending balance (in shares) | shares 619,388
Weighted  average grant date fair value  
Beginning balance (in usd per share) | $ / shares $ 121.98
RSUs granted (in usd per share) | $ / shares 277.79
RSUs vested (in usd per share) | $ / shares 173.01
RSUs forfeited/cancelled (in usd per share) | $ / shares 175.88
Ending balance (in usd per share) | $ / shares $ 175.23
v3.22.1
Other Income (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Other Income and Expenses [Abstract]      
Foreign currency (loss) gain $ (714) $ 2,275 $ (708)
(Amortization) accretion on investments (7,201) (3,082) 3,001
Interest income, net 14,730 15,859 25,185
Miscellaneous income 0 1,147 0
Other income, net $ 6,815 $ 16,199 $ 27,478
v3.22.1
Net Income per Share - Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Schedule Of Earnings Per Share Basic And Diluted [Line Items]      
Weighted average shares used in computing net income per share, basic (in shares) 153,251 150,666 147,796
Net income per share, basic (in usd per share) $ 2.79 $ 2.52 $ 2.04
Reallocation as a result of conversion of Class B to Class A common stock:      
Weighted average shares used in computing net income per share, diluted (in shares) 162,277 160,732 158,296
Net income per share, diluted (in usd per share) $ 2.63 $ 2.36 $ 1.90
Class A common stock      
Schedule Of Earnings Per Share Basic And Diluted [Line Items]      
Net income, basic $ 386,180 $ 341,866 $ 266,104
Weighted average shares used in computing net income per share, basic (in shares) 138,474 135,547 130,610
Net income per share, basic (in usd per share) $ 2.79 $ 2.52 $ 2.04
Net income, basic $ 386,180 $ 341,866 $ 266,104
Reallocation as a result of conversion of Class B to Class A common stock:      
Net income, basic 41,210 38,132 35,014
Reallocation of net income to Class B common stock 0 0 0
Net income, diluted $ 427,390 $ 379,998 $ 301,118
Conversion of Class B to Class A common stock (in shares) 14,777 15,119 17,186
Effect of potentially dilutive common shares (in shares) 9,026 10,066 10,500
Weighted average shares used in computing net income per share, diluted (in shares) 162,277 160,732 158,296
Net income per share, diluted (in usd per share) $ 2.63 $ 2.36 $ 1.90
Class B common stock      
Schedule Of Earnings Per Share Basic And Diluted [Line Items]      
Net income, basic $ 41,210 $ 38,132 $ 35,014
Weighted average shares used in computing net income per share, basic (in shares) 14,777 15,119 17,186
Net income per share, basic (in usd per share) $ 2.79 $ 2.52 $ 2.04
Net income, basic $ 41,210 $ 38,132 $ 35,014
Reallocation as a result of conversion of Class B to Class A common stock:      
Net income, basic 0 0 0
Reallocation of net income to Class B common stock 21,480 21,409 17,652
Net income, diluted $ 62,690 $ 59,541 $ 52,666
Conversion of Class B to Class A common stock (in shares) 0 0 0
Effect of potentially dilutive common shares (in shares) 9,026 10,066 10,500
Weighted average shares used in computing net income per share, diluted (in shares) 23,803 25,185 27,686
Net income per share, diluted (in usd per share) $ 2.63 $ 2.36 $ 1.90
v3.22.1
Net Income per Share - Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive (Details) - shares
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Earnings Per Share [Abstract]      
Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive (in shares) 958,476 1,045,222 1,461,255
v3.22.1
Commitments and Contingencies (Details)
$ in Millions
Mar. 13, 2017
USD ($)
Jan. 26, 2017
employee
Mar. 22, 2022
antitrust_claim
IQVIA Litigation Matter | Subsequent Event      
Long-term Purchase Commitment [Line Items]      
Pending antitrust claims against Veeva     4
Number of pending claims     5
IQVIA Litigation Matter | Minimum      
Long-term Purchase Commitment [Line Items]      
Monetary damages | $ $ 200    
Medidata Litigation Matter      
Long-term Purchase Commitment [Line Items]      
Number of former employees | employee   5  
v3.22.1
Revenues by Product - Summary of Total Revenues (Details)
$ in Thousands
12 Months Ended
Jan. 31, 2022
USD ($)
Jan. 31, 2021
USD ($)
Jan. 31, 2020
USD ($)
Jul. 31, 2021
industry
Disaggregation of Revenue [Line Items]        
Number of product areas | industry       2
Total revenues $ 1,850,777 $ 1,465,069 $ 1,104,081  
Total subscription services        
Disaggregation of Revenue [Line Items]        
Total revenues 1,483,976 1,179,486 896,294  
Commercial Solutions        
Disaggregation of Revenue [Line Items]        
Total revenues 876,458 744,856 593,562  
R&D Solutions        
Disaggregation of Revenue [Line Items]        
Total revenues 607,518 434,630 302,732  
Total professional services        
Disaggregation of Revenue [Line Items]        
Total revenues 366,801 285,583 207,787  
Commercial Solutions        
Disaggregation of Revenue [Line Items]        
Total revenues 165,086 142,003 103,825  
R&D Solutions        
Disaggregation of Revenue [Line Items]        
Total revenues $ 201,715 $ 143,580 $ 103,962  
v3.22.1
Information about Geographic Areas - Revenues by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Revenues by geography      
Total revenues $ 1,850,777 $ 1,465,069 $ 1,104,081
North America      
Revenues by geography      
Total revenues 1,063,770 838,192 607,704
Europe      
Revenues by geography      
Total revenues 509,127 400,790 310,215
Asia Pacific      
Revenues by geography      
Total revenues 225,968 183,848 151,052
Middle East, Africa, and Latin America      
Revenues by geography      
Total revenues $ 51,912 $ 42,239 $ 35,110
v3.22.1
Information about Geographic Areas - Long-Lived Assets by Geographic Area (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Jan. 31, 2021
Long-lived assets by geography    
Total long-lived assets $ 54,495 $ 53,650
North America    
Long-lived assets by geography    
Total long-lived assets 45,625 46,285
Europe    
Long-lived assets by geography    
Total long-lived assets 6,135 5,525
Asia Pacific    
Long-lived assets by geography    
Total long-lived assets 1,335 1,359
Middle East, Africa, and Latin America    
Long-lived assets by geography    
Total long-lived assets $ 1,400 $ 481
v3.22.1
401(k) Plan (Details) - USD ($)
12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Defined Contribution Plan Disclosure [Line Items]      
Total expense related defined benefit plan $ 7,000,000 $ 6,000,000 $ 4,000,000
401(k) plan      
Defined Contribution Plan Disclosure [Line Items]      
Employer maximum matching contribution amount per employee per year 2,000    
RRSP | CANADA      
Defined Contribution Plan Disclosure [Line Items]      
Employer maximum matching contribution amount per employee per year $ 2,000    
v3.22.1
Label Element Value
Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2016-02 [Member]